PROGRAMMA SES - ER Congressi final program.pdf · 15 TH INTERNATIONAL MYELOMA WORKSHOP w w w. i m w...
Transcript of PROGRAMMA SES - ER Congressi final program.pdf · 15 TH INTERNATIONAL MYELOMA WORKSHOP w w w. i m w...
15TH INTERNATIONALMYELOMAWORKSHOP
WELCOME MESSAGE
Dear Colleagues and Friends,
It is my great pleasure and honor to invite you to attend the 15th International
Myeloma Workshop to be held in Rome, Italy, from September 23rd to 26th, 2015.
During this important biannual event, the emerging advances in the biology and
treatment of multiple myeloma, as well as debates on more controversial
arguments, and consensus report will be presented.
The location of the Workshop, in the Auditorium Parco della Musica which is right
in the city centre, will ensure that you all enjoy both the meeting and the fascinating
city of Rome.
I am very much looking forward to welcoming you to Rome in September 2015!
Antonio PalumboPresident, 15th International Myeloma Workshop
AUSPICES
Con l’adesione del Presidente della Repubblica ItalianaUnder the patronage of the President of the Italian Republic
Ministero della SaluteItalian Ministry of Health
15TH INTERNATIONALMYELOMAWORKSHOP
ww
w.im
w20
15.c
om
Auditorium Parco della Musica
SEPTEMBER 23-26, 2015
TIMETABLE
Wednesday, September 23, 2015 Thursday, September 24, 2015 Friday, September 25, 2015 Saturday, September 26, 2015
07.00-08.0007.00-08.00MEET THE EXPERTS
07.00-08.00MEET THE EXPERTS
07.00-08.00MEET THE EXPERTS
08.00-09.00
09.00-10.00
08.00-10.20NEWLY DIAGNOSED MULTIPLE MYELOMAYOUNG PATIENTS
08.00-10.20NEWLY DIAGNOSED MULTIPLE MYELOMAELDERLY PATIENTS
08.00-09.00DEBATE
09.00-10.00RISING STARSAWARD
10.00-10.15BART BARLOGIE YOUNG INVESTIGATORAWARD
10.00-11.0009.45-11.00ROBERT KYLE LECTURES
10.20-10.50Coffee Break
10.20-10.50Coffee Break
10.15-10.30Coffee Break
10.50-12.20PRIME ONCOLOGY SPONSOREDSYMPOSIUM supported byTAKEDAONCOLOGYBuilding on the Foundation of ProteasomeInhibition in Multiple Myeloma
10.50-12.20CELGENE SPONSORED SYMPOSIUMThe Role of Immunomodulators in theFuture Landscape of Multiple Myeloma
10.30-11.00DEBATE
11.00-12.0011.00-13.00GENOMICSAND MICROENVIRONMENT
11.00-12.30PLENARYABSTRACT SESSION
12.00-13.0012.20-13.20Lunch
12.20-13.20Lunch
12.30-13.00CLOSING CEREMONY
13.00-14.0013.00-14.00Lunch 13.20-14.50
AMGEN SPONSORED SYMPOSIUMDelving Into the Deep – Advances in theTreatment of Multiple Myeloma in 2015
13.20-14.50JANSSEN SPONSORED SYMPOSIUMThe Clinical Rationale and Experience withMonoclonal Antibodies in Multiple Myeloma
13.00-14.00Lunch
14.00-15.00
14.00-16.00DIAGNOSTICAND RESPONSE CRITERIA
15.00-16.0014.50-16.30RELAPSED/REFRACTORY MULTIPLEMYELOMAPATIENTS
14.50-16.30IMMUNOTHERAPY
16.00-17.0016.00-16.30Coffee Break
16.30-17.00Coffee Break
16.30-17.00Coffee Break
17.00-18.00
16.30-18.00NOVARTIS SPONSORED SYMPOSIUMUnderstanding the Role of Epigenetics inthe Pathogenesis and Treatment of MultipleMyeloma
17.00-18.40ALLOGENEIC TRANSPLANTATIONANDNOVELAGENTS
17.00-18.40SPECIAL CONDITIONS
18.00-19.0018.00-18.45Waldenström's Award 18.40-19.40
POSTER SESSION I18.40-19.40POSTER SESSION II
19.00-20.00
18.45-19.15Patient Association Talks
19.15-19.30IMS General Assembly
20.00-21.0019.30-21.30Welcome Reception
2 3
09.30-09.45
OPENING CEREMONY
15TH INTERNATIONALMYELOMAWORKSHOP
54
Auditorium Parco della Musica
SEPTEMBER 23-26, 2015
FACULTY
Kenneth C. Anderson Boston, USAMichel Attal Toulouse, FranceDaniel Auclair Norwalk, USAHervé Avet-Loiseau Toulouse, FranceDavid E. Avigan Boston, USANizar J. Bahlis Calgary, CanadaLuca Baldini Milano, ItalyBart Barlogie New York, USALeif P. Bergsagel Scottsdale, USAJoan Bladé Barcelona, SpainMario Boccadoro Torino, ItalyLawrence Boise Atlanta, USASara Bringhen Torino, ItalyJamie Cavenagh London, UKMichele Cavo Bologna, ItalyRaymond L. Comenzo Boston, USAAlessandro Corso Pavia, ItalyCarlo Croce Columbus, USAFaith Davies Little Rock, USAFrancesco Di Raimondo Catania, ItalyMeletios A. Dimopoulos Athens, GreeceAngela Dispenzieri Rochester, USABrian Durie Los Angeles, USAHermann Einsele Würzburg, GermanyMonika Engelhardt Freiburg, GermanyThierry Facon Lille, FranceJean-Paul Fermand Paris, FranceRafael Fonseca Scottsdale, USAFrancesca Gay Torino, ItalyMorie A. Gertz Rochester, USAIrene M. Ghobrial Boston, USASergio A. Giralt New York, USAHartmut Goldschmidt Heidelberg, GermanyRoman Hájek Ostrava, Czech RepublicJean-Luc Harousseau Saint Denis La Plaine, FranceJian Hou Shanghai, ChinaCynthia Iglesias York, United KingdomTadao Ishida Sapporo, JapanSudar Jagannath New York, USAAndrzej Jakubowiak Chicago, USANicolaus Kroeger Hamburg, GermanyShaji K. Kumar Rochester, USARobert Kyle Rochester, USAC. Ola Landgren New York, USA
Alessandra Larocca Torino, ItalyXavier Leleu Lille, FranceSagar Lonial Atlanta, USAHeinz Ludwig Vienna, AustriaAngelo Maiolino Rio de Janeiro, BrazilFabio Malavasi Torino, ItalyThomas G. Martin San Francisco, USAMaria-Victoria Mateos Salamanca, SpainPhilip L. McCarthy Buffalo, USAGiampalolo Merlini Pavia, ItalyFortunato Morabito Cosenza, ItalyPhilippe Moreau Nantes, FranceGareth J. Morgan Little Rock, USANikhil C. Munshi Boston, USAHirokazu Murakami Maebashi, JapanPellegrino Musto Rionero in Vulture (PZ), ItalyRuben Niesvizky New York, USASusie Novis Hollywood, USAMassimo Offidani Ancona, ItalyRobert Z. Orlowski Houston, USABruno Paiva Pamplona, SpainAntonio Palumbo Torino, ItalyFrancesca Patriarca Udine, ItalyMaria Teresa Petrucci Roma, ItalyTorben Plesner Vejle, DenmarkFelipe Prósper Pamplona, SpainNoopur Raje Boston, USAS. Vincent Rajkumar Rochester, USAPaul G. Richardson Boston , USAJesús F. San Miguel Pamplona, SpainJatin J. Shah Houston, USAKazuyuki Shimizu Kakamigahara, JapanPieter Sonneveld Rotterdam, The NetherlandsAndrew Spencer Melbourne, AustraliaEdward A. Stadtmauer Philadelphia, USAA. Keith Stewart Scottsdale, USAEvangelos Terpos Athens, GreecePatrizia Tosi Rimini, ItalySteven P. Treon Boston, USANiels van den Donk Amsterdam, The NetherlandsElena Zamagni Bologna, ItalyJeffrey A. Zonder Detroit, USASonja Zweegman Amsterdam, The Netherlands w
ww
.imw
2015
.co
m
HOTELAND SHUTTLE INFORMATION DESKThe congress will provide complimentary transfer service between the hotelsbooked through the IMW hotel booking office and the Auditorium Parco dellaMusica.Transfer services will run according to the meeting schedule. One ride in themorning and one in the evening. Please look for detailed shuttle bus schedules inyour hotel lobby and on the website (www.imw2015.it).
For further information about hotel accommodation and shuttle bus serviceprovided by the meeting please visit the Hotel and Shuttle Information Desk. Thedesk is located in the Registration Area and will be open during the following hours:
Wednesday, September 23, 2015 8:00 - 19:00
Thursday, September 24, 2015 8:00 - 19:00
Friday, September 25, 2015 8:00 - 19:00
Saturday, September 26, 2015 8:00 - 14:00
7
CONGRESS INFORMATIONVENUEAuditorium Parco della MusicaViale de Coubertin, 3000196 Rome (Italy)www.auditorium.com
HOWTO REACHThe Auditorium Parco della Musica of Rome is in Viale Pietro deCoubertin, near the Palazzetto dello Sport.The Auditorium Parco della Musica is in the Flaminio district of Rome,by the Villaggio Olimpico and can be easily reached by publictransport:
Bus Routes- 910, from Termini Station and Piazza Mancini- 53, from Piazza Mancini and Piazza San Silvestro- 217, from Viale XVII Olimpiade and Termini Station- 231, from Piazza Mancini and Piazzale Canestre (in Villa Borghesepark). Only weekends- Linea "M", special bus route between Termini station and VialePietro de Coubertin Auditorium stop. From 17h 00 - every 15 mins.Last bus from the Auditorium departs at the end of last event.
Tram routes- 2, from Piazzale Flaminio and Piazza Mancini
Trains- Metro A line to the Flaminio stop then no.2 tram- Or the Ferrovia Roma-Nord train to the Piazza Euclide stop
By car- From the G.R.A. (ring-road around Rome) take the Flaminio SaxaRubra exit towards Corso di Francia- From the Lungotevere Flaminio turn off into Viale Tiziano and thenagain at the Palazzetto dello Sport.
PARKINGAREAThere are large car parking facilities by the Auditorium Parco dellaMusica with designated areas for disabled visitors.
15TH INTERNATIONALMYELOMAWORKSHOP Auditorium Parco della Musica
SEPTEMBER 23-26, 2015
ww
w.im
w20
15.c
om
AUDITORIUM PARCO DELLA MUSICAPARKING and BUS STOP
6
9
ROME INFORMATION DESKFor all the information about the city (guided tours, museums, publictransportation, etc.), please visit the Rome Information Desk. The deskis located near the bar and will be open during the following hours:
Wednesday, September 23, 2015 8:00 - 19:00
Thursday, September 24, 2015 8:00 - 19:00
Friday, September 25, 2015 8:00 - 19:00
Saturday, September 26, 2015 8:00 - 14:00
REGISTRATION FEES
The registration fee includes:
- Participation in the scientific sessions- Access to the exhibition area- Conference kit- Attendance certificate- Lunches- Coffee breaks- Welcome reception- Abstracts e-book
REGISTRATION HOURS
INDIVIDUALS and EXHIBITORSTuesday, September 22, 2015 17:00 - 20.00
Wednesday, September 23, 2015 7:00 - 18:00
Thursday, September 24, 2015 7:00 - 18:00
Friday, September 25, 2015 7:00 - 18:00
Saturday, September 26, 2015 7:00 - 13:00
MEET THE EXPERTSTuesday, September 22, 2015 8:30 - 20:00
Wednesday, September 23, 2015 7:00 - 18:00
Thursday, September 24, 2015 7:00 - 18:00
Friday, September 25, 2015 7:00 - 18:00
NURSETuesday, September 22, 2015 17:00 - 20:00
Wednesday, September 23, 2015 7:00 - 10:00
GROUPS & EXHIBITORSTuesday, September 22, 2015 8:30 - 16:30
BADGEBadges and meeting materials will be given at the counters in the registration area(ground floor of the Auditorium Parco della Musica). Remember to print and tobring with you in Rome the invitation letter and the badge barcode you received inthe “Registration Info” automatic e-mail.All registered participants, speakers, exhibitors and press staff, will be given abadge which must be worn in order to be admitted to the scientific sessions.Badge is mandatory to enter the congress area.
A self-printing system will be available in the Registration Area. Delegates, nursesand exhibitors will be able to collect their badges simply by having their personalbarcode scanned by the optical reader at the self-printing machines.Speakers and press staff are kindly requested to collect their badges at theRegistration desk.
The barcode on the badge stores the following personal information: name,surname, country and email address provided at the time of registration. It can beused by exhibitors to register visitors to their booths and to send additionalinformation on their products and services.
15TH INTERNATIONALMYELOMAWORKSHOP Auditorium Parco della Musica
SEPTEMBER 23-26, 2015
Registration Categories Onsite Registration
IMS Members € 650,00
Non-Member € 800,00
Nurses € 200,00
Exhibitors € 800,00
ww
w.im
w20
15.c
om
8
11
ATTENDANCE CERTIFICATEDelegates, nurses and speakers will be able to collect the attendancecertificates by having their personal barcode read at the self-printingmachines.The service will be available from September 23, 2015 evening.
CLOAKROOMAND LUGGAGEIn the cloakroom you can leave your belongings free of charge.The cloakroom is located in the Registration Area and will be open atthe following hours:
Wednesday, September 23, 2015 6.30 - 21:30
Thursday, September 24, 2015 6.30 - 20:00
Friday, September 25, 2015 6.30 - 20:00
Saturday, September 26, 2015 6.30 - 14:00
CATERINGLunches, coffee breaks and welcome cocktail are included in theregistration fee. No coupon is needed.Opening hours:
Wednesday, September 23, 2015 Lunch 13.00 - 14.00Coffee Break 16.00 - 16.30
Thursday, September 24, 2015 Coffee Break 10.20 - 10.50Lunch 12.20 - 13.20Coffee Break 16.30 - 17.00
Friday, September 25, 2015 Coffee Break 10.20 - 10.50Lunch 12.20 - 13.20Coffee Break 16.30 - 17.00
Saturday, September 26, 2015 Coffee Break 10.15 - 10.30Lunch 13.00 - 14.00
The IMW Welcome Cocktail is scheduled on September 23, 2015from 19.30 to 21.30 in the Cavea area. It is an outdoor standing buffetdinner.
The bar is located near the Exhibition Area and it will be open at the followinghours:
Tuesday, September 22, 2015 8.00 - 19:30
Wednesday, September 23, 2015 6.30 - 19:30
Thursday, September 24, 2015 6.30 - 19:30
Friday, September 25, 2015 6.30 - 19:30
Saturday, September 26, 2015 6.30 - 19:30
Direct payment in Euro.
PHOTOSANDAUDIO-VIDEO RECORDINGIndividual photos and audio-video recording are prohibited.Only authorized staff can provide photos and audio-video recording services.
INTERNETACCESSWiFi is available inside the Congress Area as follows:ID: IMW2015PASSWORD: TAKEDA2015An internet point will be available in the Exhibition area (see floor plan).
CASHWITHDRAWALA cash dispenser is located at the entrance of the meeting venue.Onsite payments should be made in Euro.
EXHIBITIONThe exhibition area will be open at the following hours:
Wednesday, September 23, 2015 9.00 – 21:00
Thursday, September 24, 2015 8.00 – 19:00
Friday, September 25, 2015 8.00 – 19:00
Saturday, September 26, 2015 8.00 – 14:00
15TH INTERNATIONALMYELOMAWORKSHOP Auditorium Parco della Musica
SEPTEMBER 23-26, 2015
ww
w.im
w20
15.c
om
10
13
15TH INTERNATIONALMYELOMAWORKSHOP Auditorium Parco della Musica
SEPTEMBER 23-26, 2015
ww
w.im
w20
15.c
om
12
EXHIBITIONAREAEXHIBITOR AREAAmgen B1Amgen Hospitality Suite B2Binding Site 13Bristol-Myers Squibb Co. GCelgene Corporation C1-D1Celgene Corporation Hospitality Suite C2-D2Doctors.MD Ltd. 8IMS - International Myeloma Society 10Janssen FKaryopharm Therapeutics Inc. 3Managing Myeloma 2Novartis Oncology 4-5-6-E1Novartis Oncology Hospitality Suite E2Takeda Oncology A1Takeda Oncology Hospitality Suite A216th International Myeloma Workshop 9
MEETING ROOMSSPONSOR ROOMAmgen Room B3Bristol-Myers Squibb Co. Room BBristol-Myers Squibb Co. Room ECelgene Corporation Room CCelgene Corporation Room DJanssen Room ATakeda Oncology Studio 1Takeda Oncology Studio 2Takeda Oncology Studio 3
1514
15TH INTERNATIONALMYELOMAWORKSHOP Auditorium Parco della Musica
SEPTEMBER 23-26, 2015
ww
w.im
w20
15.c
om
LANGUAGEThe Workshop will be in English with no simultaneous translation intoother languages.
ITALIAN CME CREDITSTwo Italian CME applications have been submitted as follows:
Main program (September 23-24-25-26, 2015):- Provider Studio ER Congressi SRL: ID 828-132558.- No. 11 CME credits for Physicians (Clinical Biochemistry, CardiacSurgery, Cardiology, General Surgery, Palliative Care, Haematology,Epidemiology, Pharmacology and Clinical Toxicology, MedicalGenetics, Geriatrics, Laboratory of Medical Genetics, GeneralMedicine, Internal Medicine, Nuclear Medicine, Microbiology andVirology, Oncology, Clinical Pathology, Radiotherapy), Biologists,Medical Laboratory Scientists, Nurses and Chemists.- Educational objective: “guidelines-protocols-procedures”.Poster sessions, meet the experts sessions, sponsored symposia arenot included in the submission.
In order to claim for credits attendees should:- wear a magnetic tag in order to register their presence inside thePlenary Hall. Please ask for it at the CME Registration Desk;
- attend at least the 80% of the submitted program;- complete the CME questionnaire. Please ask for it at the CMERegistration Desk on Saturday 26, 2015 morning;
- return the magnetic tag and the questionnaire at the end of themeeting.
Nursing Symposium (September 23, 2015):- Provider Studio ER Congressi SRL: ID 828-132580.- No. 5 CME credits for Nurses.- Educational objective: “guidelines-protocols-procedures”.
In order to claim for credits nurses should:- sign the attendance list at the entrance of the Teatro Studio Hall;- attend the 100% of the Nursing Symposium;- complete the CME questionnaire. Please ask for it at the entrance ofthe Teatro Studio Hall on Wednesday 23, 2015 afternoon;
- return the questionnaire at the end of the Nursing Symposium
CME certificates will be sent after the meeting by email.
SCIENTIFIC INFORMATIONEBAH CME CREDITSThe program of the “15th International Myeloma Workshop” has been reviewedand approved for CME accreditation by the European Board for Accreditation inHematology (EBAH), an independent accreditation body endorsed by EHA. TheEBAH Unit has approved this educational activity for no. 25 CME credits forPhysicians, Biologists, Medical Laboratory Scientists, Nurses and Chemists. EBAHCredit Points will be awarded for the Plenary Sessions and Meet the ExpertsSessions.To request credits, please fill out the form and return it to the registration desk atthe end of the meeting.We remind you that it is necessary to have an EBAH-CME account in order toclaim for credits. Attendees can create an EBAH-CME account registering on thewebsite: http://ebach.org even on site.
TEXTMESSAGEAND VOTING FLAGSText message system is available during the whole meeting in order to improvediscussion during the plenary sessions.Voting green/red flags for the Debate sessions are available inside the Plenary Hallin order to improve the interaction between attendees and speakers.
POSTERAREAPoster sessions will take place in the Poster Area.Opening hours:
Installation Wednesday, September 23, 2015 14.00 - 19.00Viewing Thursday, September 24, 2015 8.00 - 20.00
Friday, September 25, 2015 8.00 - 20.00Saturday, September 26, 2015 8.00 - 13.00
Best Poster Discussion Thursday, September 24, 2015 18.40 - 19.40Friday, September 25, 2015 18.40 - 19.40
Tear off Saturday, September 26, 2015 13.00 - 14.00
Posters should be installed/removed during the indicated set-up time (see above).Materials to hang posters with will be available at the poster area. The Congressprovides one board for each poster, the author is responsible for hanging and forremoving the poster. Please note that the organisers do not take any responsibilityfor returning uncollected material to the authors. There will be a poster helpdesk inthe poster area where staff will be happy to assist you.Posters will be on display in the Poster Area for three days and will be open forviewing on Thursday, Friday and Saturday.The best posters will be presented during Poster walking session on Thursday andFriday from 18.40 to 19.40.
17
15TH INTERNATIONALMYELOMAWORKSHOP Auditorium Parco della Musica
SEPTEMBER 23-26, 2015
SLIDE CENTER/SPEAKERS’AREAOpening hours:Wednesday, September 23, 2015 7.30 - 19.00
Thursday, September 24, 2015 6.30 - 19.00
Friday, September 25, 2015 6.30 - 19.00
Saturday, September 26, 2015 6.30 - 14.00
MEET THE EXPERTS SESSIONSThere will be four Meet the Experts Sessions on September 24,September 25 and September 26 from 7.00 to 8.00. The registrationis not included in the Registration Fee.It costs Euro 25,00 per day (VAT included). Each session is restrictedto 25 participants.Preregistration for these sessions is necessary. Tickets can also bepurchased during registration hours at the Registration Desk if stillavailable.All Meet the Expert Sessions are located in TEATRO STUDIO HALL asfollows:
ww
w.im
w20
15.c
om
16
Thursday, Sep 24, 2015 Friday, Sep 25, 2015 Saturday, Sep 26, 2015
Diagnostic CriteriaXavier Leleu, Elena ZamagniGREEN ROOM
Monoclonal Gammopathyof UndeterminedSignificance - SmolderingMultiple MyelomaLuca Baldini,Brian G.M. DurieGREEN ROOM
Amyloid Light-chainAmyloidosisRaymond L. Comenzo,Fortunato MorabitoGREEN ROOM
Newly Diagnosed MultipleMyeloma Patients < 65 years,High-risk Patients: How to treatMichele Cavo,Francesca PatriarcaRED ROOM
Newly Diagnosed MultipleMyeloma Fit Patients > 65years: How to treatRuben Niesvizky,Massimo OffidaniRED ROOM
WaldenströmMacroglobulinemiaPellegrino Musto,Steven P. TreonRED ROOM
Newly Diagnosed MultipleMyeloma Patients < 65 years,Low-risk Patients: How to treatMario Boccadoro,Andrzej J. JakubowiakBLUE ROOM
Newly Diagnosed MultipleMyeloma Frail Patients >65 years: How to treatSara Bringhen,Sonja ZweegmanBLUE ROOM
Bone DiseaseNoopur Raje,Patrizia TosiBLUE ROOM
Relapsed/Refractory MultipleMyeloma 1-3 Previous Linesof Therapy: How to treatFaith E. Davies,Francesco Di RaimondoYELLOW ROOM
Relapsed/RefractoryMultiple Myeloma 4-6Previous Lines of Therapy:How to treatAlessandro Corso,Sundar JagannathYELLOW ROOM
Supportive CareJoan Bladé,Maria Teresa PetrucciYELLOW ROOM
AWARDSWALDNESTRÖM’S AWARDRecognition for a lifetime achievement for contributions to multiple myelomaresearch. The award is named for Professor Jan Waldenström, who was a pioneerin treating blood cancers. The award presentation is scheduled on September 23,2015 at 18.00 in the Plenary Session.
RISING STARS AWARDThe Scientific Committee selected the best four abstracts submitted by authorsunder 35 years of age.These abstracts will be presented in plenary session on Saturday from 9.00 to10.00. The authors will receive a check of Euro 5.000,00 onsite.
BART BARLOGIE YOUNG INVESTIGATOR AWARDIn recognition to the outstanding research developed by Dr. Bart Barlogie in the fieldof multiple myeloma, the IMS Board of Directors decided to establish the BartBarlogie Young Investigator Award. This award is aimed at formally recognizingand stimulating excellence in myeloma research. The Young Investigator Awardwill be given to an investigator under the age of 40 years in recognition of theirresearch in the myeloma field. An Award of US $25,000 by the IMS will be givenat each of the International Myeloma Workshops, beginning with Rome inSeptember 2015.The award presentation is scheduled on September 26, 2015 at 10.00 in thePlenary Session.
IMWAPPA special mobile app has been developed for this congress in which you can findthe entire program and further information. Use the app to find sessions of interest,create your own program, find and read all the abstracts.Download the “IMW2015” app from the Apple App store or Google-Play.
OFFICIALWEBSITEwww.imw2015.it
CHANGESParts of the program may be changed without prior notice.
19
15TH INTERNATIONALMYELOMAWORKSHOP Auditorium Parco della Musica
SEPTEMBER 23-26, 2015
15TH INTERNATIONALMYELOMAWORKSHOP
SEPTEMBER 23 - 26, 2015Rome,Auditorium Parco della Musica
PROGRAM
www.imw2015.com
18
OPENING HOURS
Tuesday,September 22,
2015
Wednesday,September 23,
2015
Thursday,September 24,
2015
Friday,September 25,
2015
Saturday,September 26,
2015
RegistrationArea 8.30 - 20.00 6.30 - 20.00 6.30 - 20.00 6.30 - 20.00 6.30 - 14.00
Slide Center/Speakers’Area 7.30 - 19.00 6.30 - 19.00 6.30 - 19.00 6.30 - 14.00
Cloakroom 6.30 - 21.30 6.30 - 20.00 6.30 - 20.00 6.30 - 14.00
ExhibitionArea 9.00 - 21.00 8.00 - 19.00 8.00 - 19.00 8.00 - 14.00
Poster Area 8.00 - 20.00 8.00 - 20.00 8.00 - 13.00
Rome Information Desk 8.00 - 19.00 8.00 - 19.00 8.00 - 19.00 8.00 - 14.00
Hotel and Shuttle Info Desk 8.00 - 19.00 8.00 - 19.00 8.00 - 19.00 8.00 - 14.00
Bar 8.00 - 19.30 6.30 - 19.30 6.30 - 19.30 6.30 - 19.30 6.30 - 19.30
SERVICES PROVIDED
Service Name Location
Abstract e-book Congress Kit Registration Area
Cash Withdrawal Cash Dispenser Meeting Venue Entrance
City Information Rome Information Desk Exhibition Area
Cloakroom and Luggage Cloakroom Registration Area
Internet Internet Point Exhibition Area
WiFi Wireless Internet Throughout the Venue
Exhibition Information Exhibitor Help Desk Exhibition Area
Hotel and Shuttle Information Hotel and Shuttle Information Desk Registration Area
Meet the Experts Tickets Registration Desk Registration Area
Vatican Museum Tickets Registration Desk Registration Area
Poster Information Poster Help Desk Poster Area
20 21
Wednesday, September 23, 2015
09.30-09.45 OPENING CEREMONY SANTA CECILIA HALL
ROBERT KYLE LECTURESChairmen: Robert Kyle, Antonio Palumbo
09.45-10.30 Access to Innovation and Quality of Care in the Context ofEconomic Constraints: a Challenge for HealthcareJean-Luc Harousseau
10.30-11.00 How to introduce TechnologyAssessment in Clinical StudiesCynthia Iglesias
GENOMICSAND MICROENVIRONMENT SANTA CECILIA HALL
Chairmen: Gareth J. Morgan, Nikhil C. Munshi
11.00-11.20 Next Generation SequencingNikhil C. Munshi
11.20-11.40 Gene Expression ProfilePieter Sonneveld
11.40-12.00 SNP/microRNACarlo Croce
12.00-12.20 The Vk*MYC Mouse Model to study Drug and ImmunotherapyResponse and ResistanceP. Leif Bergsagel
12.20-12.40 Multiple Myeloma Biological PathwaysGareth J. Morgan
12.40-13.00 Multiple Myeloma and Bone Marrow NicheIrene M. Ghobrial
13.00-14.00 Lunch EXHIBITION AREA
CMECME CMECME
CMECME CMECME
15TH INTERNATIONALMYELOMAWORKSHOP Auditorium Parco della Musica
SEPTEMBER 23-26, 2015
DIAGNOSTICAND RESPONSE CRITERIA SANTA CECILIA HALL
Chairmen: Hervé Avet-Loiseau, S. Vincent Rajkumar
14.00-14.20 New Diagnostic Criteria for Multiple MyelomaS. Vincent Rajkumar
14.20-14.40 Flow Cytometry for Minimal Residual DiseaseBruno Paiva
14.40-15.00 Next Generation Sequencing for Minimal Residual DiseaseHervé Avet-Loiseau
15.00-15.20 Imaging TechniquesElena Zamagni
15.20-15.40 RiskAssessment and StratificationRafael Fonseca
15.40-16.00 Geriatric Assessment and StratificationAlessandra Larocca
16.00-16.30 Coffee break EXHIBITION AREA
NOVARTIS SPONSORED SYMPOSIUM SANTA CECILIA HALL
Understanding the Role of Epigenetics in the Pathogenesisand Treatment of Multiple MyelomaChairman: Jesús F. San Miguel
16.30-16.40 Welcome and Opening RemarksJesús F. San Miguel
16.40-16.55 Introduction to Epigenetics and its Role in the Pathogenesis ofHematologic MalignanciesFelipe Prósper
16.55-17.15 Rationale for Targeting Epigenetic Mechanisms in MultipleMyelomaAndrew Spencer
CMECME CMECME
15TH INTERNATIONALMYELOMAWORKSHOP
2322
Auditorium Parco della Musica
17.15-17.35 Clinical Update on Pan-Deacetylase Inhibitors in Multiple MyelomaJamie D. Cavenagh
17.35-17.55 Opportunities for Novel Combinations withAgents TargetingEpigenetic MechanismsHermann Einsele
17.55-18.00 Closing RemarksJesús F. San Miguel
Chairmen: Kenneth C. Anderson, Robert Kyle SANTA CECILIA HALL
18.00-18.45 Waldenström's Award
18.45-19.15 Patient Association Talks
• International Myeloma FoundationSusie Novis
• Multiple Myeloma Research FoundationDaniel Auclair
19.15-19.30 IMS General Assembly
19.30-21.30 Welcome Reception CAVEA AREA
SEPTEMBER 23-26, 2015
CMECME CMECME
Qursday, September 24, 2015
MEET THE EXPERTS TEATRO STUDIO HALL
Simultaneous sessions in four rooms
07.00-08.00 Diagnostic Criteria GREEN ROOM
Xavier Leleu, Elena Zamagni
07.00-08.00 Newly Diagnosed Multiple Myeloma Patients < 65 years, RED ROOM
High-risk Patients: How to treatMichele Cavo, Francesca Patriarca
07.00-08.00 Newly Diagnosed Multiple Myeloma Patients < 65 years, BLUE ROOM
Low-risk Patients: How to treatMario Boccadoro, Andrzej J. Jakubowiak
07.00-08.00 Relapsed/Refractory Multiple Myeloma 1-3 Previous YELLOW ROOM
Lines of Therapy: How to treatFaith E. Davies, Francesco Di Raimondo
NEWLY DIAGNOSED MULTIPLE MYELOMA SANTA CECILIA HALL
YOUNG PATIENTSChairmen: Michele Cavo, Angelo Maiolino
08.00-08.20 Optimal InductionMichel Attal
08.20-08.40 Single-tandem TransplantationHermann Einsele
08.40-09.00 Optimal Consolidation TherapyMichele Cavo
09.00-09.20 Transplant Eligible MaintenancePhilip L. McCarthy
09.20-09.40 Ongoing Studies/Open Questions inAmericaSergio A. Giralt
09.40-10.00 Ongoing Studies/Open Questions in EuropeRoman Hájek
10.00-10.20 Ongoing Studies/Open Questions inAsia PacificJian Hou
10.20-10.50 Coffee break EXHIBITION AREA
CMECME
CMECME CMECME
15TH INTERNATIONALMYELOMAWORKSHOP
25
Auditorium Parco della Musica
PRIME ONCOLOGY SPONSORED SYMPOSIUM SANTA CECILIA HALL
Supported by TAKEDAONCOLOGYBuilding on the Foundation of Proteasome Inhibition inMultiple MyelomaChairman: Mario Boccadoro
10.50-10.52 Welcome and IntroductionMario Boccadoro
10.52-10.55 “Myeloma Guru”Questions
10.55-11.10 Targeting the Ubiquitin-proteasome System in Multiple Myeloma:Examining the Roots of SuccessPaul G. Richardson
11.10-11.15 “Myeloma Guru”Questions
11.15-11.30 Challenges and Solutions with First-generation ProteasomeInhibition: Practical StrategiesMaría-Victoria Mateos
11.30-11.35 “Myeloma Guru”Questions
11.35-11.50 Second-generation Proteasome Inhibition: What a Difference aGeneration makesMario Boccadoro
11.50-11.55 “Myeloma Guru”Questions
11.55-12.10 Implications of Oral Proteasome Inhibition: Impact on PatientsShaji K. Kumar
12.10-12.20 Audience Questions and Faculty Panel Discussion
12.20 Adjourn
12.20-13.20 Lunch EXHIBITION AREA
SEPTEMBER 23-26, 2015
AMGEN SPONSORED SYMPOSIUM SANTA CECILIA HALL
Delving Into the Deep –Advances in the Treatmentof Multiple Myeloma in 2015Chairman: Antonio Palumbo
13.20-13.25 Welcome and IntroductionAntonio Palumbo
13.25-13.42 Reaching Beyond Overall Response in Patients with MultipleMyelomaPhilippe Moreau
13.42-13.59 Two-drug Combinations in the Treatment of Multiple MyelomaMeletios A. Dimopoulos
13.59-14.16 Three-drug Combinations in the Treatment of Multiple MyelomaA. Keith Stewart
14.16-14.33 The Evolving Role of Proteasome Inhibition in Multiple MyelomaAntonio Palumbo
14.33-14.48 Panel Discussion
14.48-14.50 Summary and CloseAntonio Palumbo
RELAPSED/REFRACTORY MULTIPLE SANTA CECILIA HALL
MYELOMAPATIENTSChairmen: Joan Bladé, Sundar Jagannath
14.50-15.10 How I treat Relapsed/Refractory Multiple Myeloma, SequenceStrategy, Patient SelectionRobert Orlowski
15.10-15.30 How I treat Refractory Disease and Extramedullary DiseaseJoan Bladé
15.30-15.50 How I treat Serious Adverse EventsHeinz Ludwig
15.50-16.10 How I use Bone SupportEvangelos Terpos
16.10-16.30 How I use Supportive Care and PalliationFrancesca Gay
16.30-17.00 Coffee break EXHIBITION AREA
CMECME CMECME
24
15TH INTERNATIONALMYELOMAWORKSHOP
2726
Auditorium Parco della Musica
ALLOGENEIC TRANSPLANTATIONAND SANTA CECILIA HALL
NOVELAGENTSChairmen: Nicolaus Kroeger, Andrew Spencer
17.00-17.20 Significance of Allogenic Stem Cell TransplantationNicolaus Kroeger
17.20-17.40 Selective Histone Deacetylase InhibitorNoopur Raje
17.40-18.00 Inhibitors (KPT – KSP)Jatin J. Shah
18.00-18.20 Inhibitors (BCL2 - MCL1 - CDK)Lawrence Boise
18.20-18.40 Targeting Oncogenic Pathways in Myeloma (MEK- PI3K -AKT)Andrew Spencer
POSTER SESSION I POSTER AREA
18.40-19.40 Multiple Myeloma Genomics, Diagnosis, Prognosis, ImagingChairman: Nizar J. Bahlis
18.40-19.40 Multiple Myeloma Therapy in Newly Diagnosed Patients includingTransplantationChairman: Andrzej J. Jakubowiak
18.40-19.40 Epidemiology, QoL, Toxicities, and Other Plasma Cell DyscrasiasChairman: Raymond L. Comenzo
SEPTEMBER 23-26, 2015
CMECME CMECME Friday, September 25, 2015
MEET THE EXPERTS TEATRO STUDIO HALL
Simultaneous sessions in four rooms
07.00-08.00 Monoclonal Gammopathy of Undetermined GREEN ROOM
Significance - Smoldering Multiple MyelomaLuca Baldini, Brian G.M. Durie
07.00-08.00 Newly Diagnosed Multiple Myeloma Fit Patients > 65 years: RED ROOM
How to treatRuben Niesvizky, Massimo Offidani
07.00-08.00 NewlyDiagnosedMultipleMyelomaFrail Patients > 65 years: BLUE ROOM
How to treatSara Bringhen, Sonja Zweegman
07.00-08.00 Relapsed/Refractory Multiple Myeloma 4-6 Previous YELLOW ROOM
Lines of Therapy: How to treatAlessandro Corso, Sundar Jagannath
NEWLY DIAGNOSED MULTIPLE MYELOMA SANTA CECILIA HALL
ELDERLY PATIENTSChairmen: Hirokazu Murakami, Paul G. Richardson
08.00-08.20 Debate - Change Therapy for High/Low Risk Patients - YesS. Vincent Rajkumar
08.20-08.40 Debate - Change Therapy for High/Low Risk Patients - NoPaul G. Richardson
08.40-09.00 Optimal Therapy for Fit Elderly PatientsRuben Niesvizky
09.00-09.20 Optimal Therapy for Unfit Elderly PatientsSonja Zweegman
09.20-09.40 Ongoing Studies/Open Questions inAmericaMorie A. Gertz
CMECME CMECME
CMECME
15TH INTERNATIONALMYELOMAWORKSHOP
29
Auditorium Parco della Musica
09.40-10.00 Ongoing Studies/Open Questions in EuropeMonika Engelhardt
10.00-10.20 Ongoing Studies/Open Questions inAsia PacificTadao Ishida
10.20-10.50 Coffee break EXHIBITION AREA
CELGENE SPONSORED SYMPOSIUM SANTA CECILIA HALL
The Role of Immunomodulators in the Future Landscapeof Multiple MyelomaChairman: Michele Cavo
10.50-10.55 WelcomeMichele Cavo
10.55-11.10 Multiple Myeloma – Coping with a Disrupted Immune EnvironmentKenneth C. Anderson
11.10-11.25 Continuous Therapy for Elderly Newly Diagnosed Multiple MyelomaThierry Facon
11.25-11.40 IMiD-based Triplet Therapy for Multiple MyelomaSagar Lonial
11.40-11.55 Clonal Evolution – Disease ChallengesGareth J. Morgan
11.55-12.10 Beyond Lenalidomide: PomalidomideMeletios A. Dimopoulos
12.10-12.20 Questions and Discussion
12.20-13.20 Lunch EXHIBITION AREA
SEPTEMBER 23-26, 2015
28
JANSSEN SPONSORED SYMPOSIUM SANTA CECILIA HALL
The Clinical Rationale and Experience with MonoclonalAntibodies in Multiple MyelomaChairmen: Antonio Palumbo, Jesús F. San Miguel
What is the Role for Monoclonal Antibodies in Multiple Myeloma?13.20-13.30 Understanding the Biological Rationale
Fabio Malavasi
13.30-13.40 What do the Preclinical Data tell us?Sagar Lonial
13.40-13.50 Panel Discussion
Current Clinical Experience with anti-CD38 Monoclonal Antibodies:13.50-14.00 Single Agent Activity
Jesús F. San Miguel
14.00-14.10 Combination StudiesAntonio Palumbo
14.10-14.30 Practical Management Consideration for Patients Receivinganti-CD38 Monoclonal AntibodiesPhilippe Moreau
14.30-14.50 Panel Discussion
IMMUNOTHERAPY SANTA CECILIA HALL
Chairmen: David E. Avigan, Thierry Facon
14.50-15.10 SLAMF7 Combinational Monoclonal Antibodies TherapyThierry Facon
15.10-15.30 CD38, Novel Monoclonal Antibodies Targets, ImmunotoxinThomas G. Martin
15.30-15.50 PD1 - PDL1 - VaccineDavid E. Avigan
15.50-16.10 CAR-TEdward A. Stadtmauer
16.10-16.30 Bispecific Monoclonal AntibodiesJeffrey A. Zonder
16.30-17.00 Coffee break EXHIBITION AREA
CMECME CMECME
15TH INTERNATIONALMYELOMAWORKSHOP
31
Auditorium Parco della Musica
SPECIAL CONDITIONS SANTA CECILIA HALL
Chairmen: Angela Dispenzieri, Jean-Paul Fermand
17.00-17.20 Monoclonal Gammopathy of Undetermined SignificanceAngela Dispenzieri
17.20-17.40 Smoldering Multiple MyelomaMaría-Victoria Mateos
17.40-18.00 Primary Plasma Cell LeukemiaNiels van de Donk
18.00-18.20 Amyloid Light-chainAmyloidosisGiampaolo Merlini
18.20-18.40 Waldenström MacroglobulinemiaSteven P. Treon
POSTER SESSION II POSTER AREA
18.40-19.40 Multiple Myeloma Biology, Pathophysiology, Preclinical Studies,Bone DiseaseChairman: Noopur Raje
18.40-19.40 Multiple Myeloma Therapy in Newly Diagnosed Patients excludingTransplantationChairman: Heinz Ludwig
18.40-19.40 Multiple Myeloma Therapy Relapsed/Refractory PatientsChairman: Torben Plesner
SEPTEMBER 23-26, 2015
CMECME CMECME Saturday, September 26, 2015
MEET THE EXPERTS TEATRO STUDIO HALL
Simultaneous sessions in four rooms
07.00-08.00 Amyloid Light-chainAmyloidosis GREEN ROOM
Raymond L. Comenzo, Fortunato Morabito
07.00-08.00 Waldenström Macroglobulinemia RED ROOM
Pellegrino Musto, Steven P. Treon
07.00-08.00 Bone Disease BLUE ROOM
Noopur Raje, Patrizia Tosi
07.00-08.00 Supportive Care YELLOW ROOM
Joan Bladé, Maria Teresa Petrucci
DEBATE SANTA CECILIA HALL
Chairmen: Brian G.M. Durie, Antonio Palumbo
08.00-08.15 Biomarker to change Therapy Minimal Residual Disease/Imagingvs FISH/Age - in Favor of Minimal Residual Disease/ImagingC. Ola Landgren
08.15-08.30 Biomarker to change Therapy Minimal Residual Disease/Imagingvs FISH/Age - in Favor of FISH/AgePieter Sonneveld
08.30-08.45 Can we cure Multiple Myeloma by 2020? YesBart Barlogie
08.45-09.00 Can we cure Multiple Myeloma by 2020? NoHartmut Goldschmidt
RISING STARSAWARD SANTA CECILIA HALL
Chairmen: Brian G.M. Durie, Antonio Palumbo
09.00-09.15 RS-001
Hedgehog Pathway over Expression Identifies Myeloma Patientswith worse PrognosisMarina Martello
CMECME
CMECME CMECME
CMECME CMECME
30
15TH INTERNATIONALMYELOMAWORKSHOP
3332
Auditorium Parco della Musica
09.15-09.30 RS-002
Preclinical Analysis of Feasibility and Efficacy of CS1 DirectedCAR T cell Therapy in Multiple Myeloma in theAutologous SettingSophia Danhof
09.30-09.45 RS-003
Carfilzomib and Dexamethasone in Untreated SymptomaticMultiple MyelomaPeter Forsberg
09.45-10.00 RS-004
Ribosomal dysfunction inAL amyloidosis: Gene ExpressionProfile Meta-AnalysisFedor Kryukov
BARTBARLOGIE YOUNG INVESTIGATIONAWARD10.00-10.15 Chairmen: Kenneth C. Anderson, Bart Barlogie, Joan Bladé
10.15-10.30 Coffee break EXHIBITION AREA
DEBATE SANTA CECILIA HALL
Chairmen: Mario Boccadoro, Hermann Einsele
10.30-10.45 How to incorporate the Newest Agents Combo vs Sequence -in Favor of ComboFaith E. Davies
10.45-11.00 How to incorporate the Newest Agents Combo vs Sequence -in Favor of SequenceShaji K. Kumar
PLENARYABSTRACT SESSION SANTA CECILIA HALL
Chairmen: Mario Boccadoro, Hermann Einsele
11.00-11.15 OP-001
AMeta-Analysis Investigating the Impact of Minimal ResidualDisease (MRD) Status on Survival Outcomes in Patients withMultiple Myeloma (MM) whoAchieve Complete Response (CR)Nikhil Munshi
SEPTEMBER 23-26, 2015
CMECME CMECME
CMECME CMECME
11.15-11.30 OP-002
Genome-scale CRISPR-Cas9 Knockout Studies to characterize theMechanisms of Myeloma Cell Treatment ResistanceYiguo Hu
11.30-11.45 OP-003
Carfilzomib (CFZ), Lenalidomide (LEN), and Dexamethasone (DEX)(KRd) combined withAutologous Stem Sell Transplant (ASCT) showsEmproved Efficacy compared with KRd without ASCT in NewlyDiagnosed Multiple Myeloma (NDMM)Andrzej J. Jakubowiak
11.45-12.00 OP-004
Early Mortality in Elderly Patients with Newly Diagnosed MultipleMyeloma Treated with Novel AgentsAlessandra Larocca
12.00-12.15 OP-005
Phase 1, Multicenter, Open-label, Dose-escalation, CombinationStudy (NCT02103335) of Pomalidomide (POM), Marizomib(MRZ, NPI-0052), and Dexamethasone (DEX) in Patients withRelapsed and Refractory Multiple Myeloma (MM);Study NPI-0052-107 Preliminary ResultsAndrew Spencer
12.15-12.30 OP-006
The Genomic and Transcriptional Landscape of Waldenström’sMacroglobulinemia Impacts Disease Presentation, Overall Survivaland Therapeutic ResponseZachary Hunter
12.30-13.00 CLOSING CEREMONY SANTA CECILIA HALL
13.00-14.00 Lunch EXHIBITION AREA
34 35
Wednesday, September 23, 2015
10.45-11.00 Welcome and OpenElena Ponticelli, Tracy King
MANAGING TOXICITIESAND SYMPTOMS TEATRO STUDIO HALL
Chairmen: Daniela Klarica, Tiffany Richards
11.00-11.40 Keeping Patients on Treatment: Management of ToxicitiesRelated to New Therapies and Challenges of SymptomManagement ResearchBeth Faiman
11.40-12.00 Toxicities Associated with SQ Bortezomib: an Update ofthe Italian ExperienceAlessandra Malfitano
12.00-12.20 Evidenced Based Practice for Central Line Care: Impact ofNew Therapies on Utilization of VenousAccess Devices byPatients with MyelomaAnnalisa Bernardini
12.20-12.40 The Devils in the Dex: the Experience of High DoseDexamethasone and Implications for PRO Tool DevelopmentTracy King
12.40-13.00 “We are the Nurses all the Time”: the Experience and SupportiveCare Needs of the Family in the Era of Novel Myeloma TherapiesMonica Morris
13.00-14.00 Lunch
15TH INTERNATIONALMYELOMAWORKSHOP Auditorium Parco della Musica
SEPTEMBER 23-26, 2015
Annalisa Bernardini Torino, ItalyBeth Faiman Cleveland, USATracy King Sidney, AustraliaDaniela Klarica Melbourne, AustraliaAlessandra Malfitano Torino, ItalyMonica Morris Edinburgh, United KingdomElena Ponticelli Torino, ItalyTiffany Richards Houston, USAJoseph Tariman Chicago, USA
PROGRAM
FACULTY
2nd MYELOMANURSING SYMPOSIUM
36 37
15TH INTERNATIONALMYELOMAWORKSHOP Auditorium Parco della Musica
SEPTEMBER 23-26, 2015
ABSTRACT SESSION TEATRO STUDIO HALL
Chairman: Beth Faiman
14.00-14.20 NO-001
Lack of Health Maintenance Exams and Risk: an Internet-BasedSurvey on Health Maintenance and Preventive Care Patterns inPatients with MyelomaJoseph D. Tariman
14.20-14.40 NO-002
ACAM doApproach: the attitudes, Use and Disclosure of the Use ofComplementary andAlternative Medicine (CAM) in those with myelomaTracy King
14.40-15.00 NO-003
APilot Placebo Controlled Study to Estimate the Effect Size ofGlutamine to Prevent Peripheral Neuropathy in Multiple MyelomaBeth Faiman
15.00-15.20 NO-004
Development of a Nurse Led Community based Bortezomib Programfor Multiple Myeloma (MM)Daniela Klarica
15.20-15.40 NO-005
Aplasia on the own Couch at Home in Multiple Myeloma Patientsafter Autologous Stem Cell TransplantationIris Agreiter
15.40-16.00 NO-006
Cellular Immunotherapy for Myeloma using Chimeric AntigenReceptor Modified T Cells (CARs)Patricia Mangan
16.00-16.30 Coffee break
NURSING PLENARY TEATRO STUDIO HALL
Chairman: Monica Morris
16.30-17.15 Integrating Myeloma Genomics into Nursing Practice: PatientEducation and Shared Decision MakingJoseph D. Tariman
17.15-17.35 Formation of International Nurses SocietyTracy King
17.35-17.45 IMW 2017 New Delhi Summary and CloseElena Ponticelli, Tracy King
GENERAL INFORMATION OF THE NURSING SYMPOSIUM
VENUETeatro Studio HallAuditorium Parco della MusicaViale de Coubertin, 3000196 Rome (Italy)www.auditorium.com
POSTERPoster session will take place in the Teatro Studio Hall:
InstallationWednesday, September 23, 2015 9.30 - 10.30 Teatro Studio Hall
ViewingWednesday, September 23, 2015 10.30 - 18.00 Teatro Studio HallThursday, September 24, 2015 8.00 - 20.00 Poster AreaFriday, September 25, 2015 8.00 - 20.00 Poster AreaSaturday, September 26, 2015 8.00 - 13.00 Poster Area
Tear offSaturday, September 26, 2015 13.00 -14.00 Poster Area
Posters should be installed in Teatro Studio Hall, on the back of the room in orderto make posters available during the Nursing Symposium. At the end of thesymposium, the Organizing Secretariat staff will move posters in the Poster Area ofthe meeting.Materials to hang posters with will be available in Teatro Studio Hall. The Congressprovides one board for each poster. The author is responsible for hanging and forremoving the poster. Please note that the organisers do not take any responsibilityfor returning uncollected material to the authors. There will be a poster helpdeskwhere staff will be happy to assist you.
38 39
INTERIM ANALYSIS OF THE MMRF COMMPASS STUDY: COM-PREHENSIVE CHARACTERIZATION OF MULTIPLE MYELOMAPATIENTS AT DIAGNOSIS REVEALS DISTINCT MOLECULARSUBTYPESAND CLINICAL OUTCOMES
MOLECULAR RISK STRATIFICATION OF 1,036 CASES FROM THENCRIMYELOMAXI TRIALUSINGTHEALL-MOLECULARDIAGNOSTICTOOLMYMAP (MYELOMAMLPAAND TRANSLOCATION PCR)
NONINVASIVE DIAGNOSIS OF ACTIONABLE MUTATIONS BY DEEPSEQUENCING OF CIRCULATING CELL FREE DNA (CFDNA) INMULTIPLE MYELOMA (MM)
RARE HIGH RISK IGH TRANSLOCATIONS IN NEWLY DIAGNOSEDMULTIPLE MYELOMA (MM): CYTOGENETIC CHARACTERIZATIONAND RELEVANCE ON PROGNOSIS
JUMPING TRANSLOCATIONS OF 1Q12 IN MULTIPLE MYELOMA:UNEXPECTED INTRA-CLONALHETEROGENEITYOFCOPYNUMBERABERRATIONS IN THE 1Q21-31 REGION
CIRCULATINGEXOSOMALMICRORNASARECRITICALPROGNOSTICMARKERS INDEPENDENTOFCYTOGENETICSAND INTERNATIONALSTAGING SYSTEM IN MULTIPLE MYELOMA
GENE EXPRESSION PROFILE OF MULTIPLE MYELOMA PATIENTSWITH POOR RESPONSE TO BORTEZOMIB INDUCTION THERAPY INTHE HOVON65/GMMG-HD4 STUDY
THE IMPACT OF NORMAL PLASMA CELL RECOVERY ON PRO-GRESSION-FREE AND OVERALL SURVIVAL IN MYELOMA PATIENTSAFTERASCT
MULTIPLE MYELOMA SUBTYPING THAT ASSOCIATES NORMAL B-CELL SUBSET PHENOTYPES, DO CORRELATE TO DISEASE STAGEAND PROGNOSIS - INDICATION OF REVERSIBLE PHENOTYPICPLASTICITYASAHALLMARK
POSTER
1. Multiple Myeloma Genomics, Diagnosis, Prognosis, Imaging
POSTER DISCUSSION SESSIONChairman: Nizar J. Bahlis
J. Keats
M.F. Kaiser
R. Kaedbey
G. Marzocchi
J. Sawyer
S. Manier
M. Van Duin
A.C. Rawstron
H.E. Johnsen
BP-001
BP-002
BP-003
BP-004
BP-005
BP-006
BP-008
BP-009
BP-010
15TH INTERNATIONALMYELOMAWORKSHOP Auditorium Parco della Musica
SEPTEMBER 23-26, 2015
15TH INTERNATIONALMYELOMAWORKSHOP
4140 4140
Auditorium Parco della Musica
SEPTEMBER 23-26, 2015
USEFULNESS OF WHOLE-BODY DIFFUSION-WEIGHTED MRI (WB-MRI) WITH APPARENT DIFFUSION COEFFICIENT (ADC) IN THE DIF-FERENTIATION OF MONOCLONALGAMMOPATHIES
DEVELOPMENTOFACOST-EFFECTIVE CLINICALASSAY TO SIMUL-TANEOUSLY SCREEN, QUANTITATE AND ISOTYPE M-PROTEINS INREAL-TIME USING MALDI-TOF
SERUM HEAVY LIGHT CHAIN RATIO NORMALIZATION AMONGMULTIPLE MYELOMAPATIENTSACHIEVING SCR
SMOLDERING MULTIPLE MYELOMA: IMPACT OF THE EVOLVINGPATTERN ON EARLY PROGRESSION
EARLY DIAGNOSIS OF MULTIPLE MYELOMA-PROJECT CRAB OFCZECH MYELOMAGROUP(CMG)
ANOVELAPPROACHTOSTUDYEVOLUTIONOFDRUGRESISTANCEAND OPTIMUM THERAPY IN MULTIPLE MYELOMA
POLYMORPHISMS WITHIN IRF4 ENCODING GENE AND ITS SI-GNIFICANCE FOR PATIENTS WITH MULTIPLE MYELOMA
A SIMPLE MODEL TO PREDICT SURVIVAL USING AGE, COMOR-BIDITIES AND FUNCTIONAL STATUS IN PATIENTS WITH MULTIPLEMYELOMA (MM)
DIGITAL PCR FOR MRD DETECTION OF MYELOMA
CLINICAL SIGNIFICANCE OF CIRCULATING PLASMA CELLS INMYELOMA; 6-COLOR MULTIPARAMETER FLOWCYTOMETRYANALYSIS
ANALYSIS OF CD138+ PLASMA CELL PERCENTAGE IN BONEMARROW SECTION USING IMAGEANALYZER : DISCREPANCIES OFBONEMARROWPLASMACELLCOUNT BETWEENASPIRATIONANDBIOPSY SECTION IN MULTIPLE MYELOMA
CLINICALANALYSISOFMULTIPLEMYELOMAPATIENTSWITH BONE-RELATED EXTRAMEDULLARY DISEASE - A LONGITUDINAL STUDYON 834 CONSECUTIVE PATIENTS IN ASINGLE CENTER OF CHINA
EXPLORING THE ROLE OF SHELTERIN COMPLEX AND TE-LOMERASEACTIVITY IN MULTIPLE MYELOMA
PRESENTATION FREE LIGHT CHAIN LEVELS AND AGE ARE THESTRONGEST PREDICTORS OF RENAL FUNCTION IN NEWLYDIAGNOSED MULTIPLE MYELOMAPATIENTS
ASSOCIATION BETWEEN MAGNETIC RESONANCE IMAGINGPATTERNS AND BASELINE DISEASE FEATURES IN MULTIPLEMYELOMA: ANALYZING SURROGATES OF TUMOR MASS ANDBIOLOGY
J.M. Hernandez
D.L. Murray
A.K. Nooka
I. Isola
J. Straub
A. Silva
A. Butrym
P. Milani
S. McAuliffe
M. Fujisawa
N. Lee
D. Shuhui
R. Kumar
P. Yadav
E.K. Mai
PO-016
PO-017
PO-018
PO-019
PO-020
PO-021
PO-022
PO-023
PO-024
PO-025
PO-026
PO-027
PO-028
PO-029
PO-030
TARGETED SEQUENCING OF RELAPSED/REFRACTORY MYELOMAPATIENTS IDENTIFIES AN ENRICHMENT OF MUTATIONS IN MAPKAND CEREBLON PATHWAYS
(GERMLINE) MUTATIONS IN RECEPTOR TYROSINE KINASES: APROGNOSTIC MARKER IN MULTIPLE MYELOMA?
IMPROVED PROGNOSIS IN MULTIPLE MYELOMABYASYSTEMATICCOMBINATORIAL APPROACH: COMBINING EMC92 GENECLASSIFIERWITH ISSRESULTS IN PREDICTIONOFHIGH-AND LOW-RISK MULTIPLE MYELOMA
MINIMALRESIDUALDISEASE INTRANSPLANT INELIGIBLEMYELOMAPATIENTS: RESULTS FROM THE UK NCRI MYELOMAXI TRIAL
RELATIONSHIP BETWEEN PRESENCE OF OSTEOLYTIC LESIONS,CYTOGENETIC FEATURES AND BONE MARROW LEVELS OFCYTOKINES AND CHEMOKINES IN MULTIPLE MYELOMA PATIENTS:ROLE OF CHEMOKINE (C-C MOTIF) LIGAND 20AS NEWMARKEROFBONE DISEASE
PROGNOSTIC IMPACT OF CIRCULATING PLASMA CELLS ONSURVIVAL OF PATIENTS WITH MULTIPLE MYELOMA
ASSESSMENT OF BIOCHEMICAL RESPONSE FOR MULTIPLEMYELOMA (MM) PATIENTS TREATED WITH DARATUMUMAB:PROPOSAL IN CASSIOPEIA STUDY, IFM 2015/01
WHOLE-EPIGENOME ANALYSIS IN MULTIPLE MYELOMA REVEALSDNAHYPERMETHYLATION OF B CELL-SPECIFIC ENHANCERS
THE SPECTRUM AND CLINICAL IMPACT OF EPIGENETIC MODIFIERMUTATIONS IN MYELOMA
MYC PROTEIN EXPRESSION IN MULTIPLE MYELOMA: CLINICOPA-THOLOGICAL FEATURESAND PROGNOSTIC IMPACT
MORNING URINE AS AN ALTERNATIVE TO 24-HOUR URINE ELEC-TROPHORESIS? RENAL LESIONS ASSESSMENT, MONOCLONALPEAK DETECTIONAND QUANTIFICATION COMPARISONS
REVISED INTERNATIONAL STAGING SYSTEM APPLIED TOJAPANESE PATIENTS: A MULTICENTER RETROSPECTIVE COLLA-BORATIVE STUDY OF THE JAPANESE SOCIETY OF MYELOMA
BODY FAT PERCENTAGE AND DISTRIBUTION AS PREDICTIVEFACTORS FOR TREATMENT RESPONSE – A RETROSPECTIVESTUDY IN PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA
HEAVY/LIGHT CHAIN ANALYSIS FOR RESPONSE MONITORING INMULTIPLE MYELOMA PATIENTS: COMPARISONS WITH IMMUNO-FIXATION, SERUM FREE LIGHT CHAIN, AND MULTICOLOR FLOW-CYTOMETRYANALYSIS
K.M. Kortüm
S. Keppler
R. Kuiper
R. De Tute
B. Dalla Palma
M. Granell
H. Caillon
X. Agirre
C. Pawlyn
H.E.H. Møller
P. Boulard
S. Ozaki
J. Groß
K. Matsue
PO-001
PO-002
PO-003
PO-004
PO-006
PO-007
PO-008
PO-009
PO-010
PO-011
PO-012
PO-013
PO-014
PO-015
POSTER SESSION
15TH INTERNATIONALMYELOMAWORKSHOP
4342
Auditorium Parco della Musica
SEPTEMBER 23-26, 2015
CYTOGENETIC ABNORMALITIES OF UNDETERMINED CLINICAL SI-NIGICANCE CORRELATE WITH POOR PROGNOSIC FACTORS INMULTIPLE MYELOMA
WHOLE-EXOME SEQUENCING AND TRANSCRIPTOME ANALYSISFOR IGM MULTIPLE MYELOMA
EARLY EVALUATION OF RESPONSE BY SERUM FREE LIGHT CHAIN(FLC) AND HEVYLITE (HLC) IN INTACT IMMUNOGLOBULIN (IIG)MULTIPLE MYELOMA (MM): PREDICTION OF OUTCOME
ASSESSMENTOFTIME FROMONSETOF FIRSTSYMPTOMSTOTHEFINAL DIAGNOSIS OF MULTIPLE MYELOMA (MM) - POSSIBLE RISKSAND FUTURE SOLUTIONS
ASSESSING PROGRESSIVE DISEASE IN MYELOMAPATIENTS WITHWHOLE-BODY DIFFUSION-WEIGHTED IMAGING AT 3.0 T: A PRO-SPECTIVE IMAGING STUDY COMPARING WHOLE BODY T1-WI, T2-STIR-WI AND LABORATORY FINDINGS
MYELOMA MULTIPLE (MM) IGA SUBTYPE. USEFULNESS OFHEAVY/LIGHT IGAK/IGAL QUANTIFICATION FOR DIAGNOSIS ANDFOLLOW-UP
LOW BECLIN-1 EXPRESSION PREDICTS IMPROVED OVERALLSURVIVAL IN PATIENTS TREATED WITH IMMUNE-MODULATORYDRUGS FORMULTIPLEMYELOMAAND IDENTIFIESAUTOPHAGY IN-HIBITION AS A PROMISING POTENTIALLY DRUGGABLE NEW THE-RAPEUTIC TARGET. AN ANALYSIS FROM THE AUSTRIAN MYELOMAREGISTRY (AMR)
NORMALIZATION OF SERUM FREE LIGHT CHAIN RATIO AFTER AU-TOLOGOUSSTEMCELLTRANSPLANTATION INMULTIPLEMYELOMAASAMAJOR CRITERIARESPONSE
RESULTS FROM FIRST PILOT CEQAS FOR MYELOMA GENETICDIAGNOSIS
COMPARISON OF FREELITE AND N LATEX SERUM FREE LIGHTCHAINASSAYS IN SUBJECTSWITH ENDSTAGERENALDISEASEONHAEMODIALYSIS
CLONAL CHANGES ARE FREQUENTLY DETECTED BY CY-TOPLASMIC IMMUNOGLOBULIN-FLUORESCENCE IN SITU HYBRI-DIZATION WITH PROGRESSION OF MULTIPLE MYELOMA
PROGNOSTIC VALUEOFTHE INVERSEPLATELET-TO-LYMPHOCYTERATIO (IPLR) IN PATIENTS WITH MULTIPLE MYELOMA WHO WERETREATED UPFRONTWITHANOVEL-AGENT-CONTAINING REGIMEN
EARLY MORTALITY IN THE PATIENTS WITH MULTIPLE MYELOMAWHO WERE TREATED UPFRONT WITH A NOVEL AGENT-CONTAINING REGIMEN
Y.K. Lee
D. Ryu
S. SavaryBélanger
G. Graziani
S. Pans
M. AndradeCampos
W. Willenbacher
S. Gentili
P.J. Talley
A. Kennard
S. Hwang
J.J. Lee
J.J. Lee
PO-044
PO-045
PO-046
PO-047
PO-048
PO-049
PO-050
PO-051
PO-052
PO-053
PO-054
PO-055
PO-056
COMPARISON OF MINIMAL RESIDUAL DISEASE DETECTION INMULTIPLE MYELOMA BETWEEN MULTIPARAMETER FLOWCYTOMETRYAND DEEP-SEQUENCING
GAH SCALE IS ASIMPLE, COMPREHENSIVEASSESSMENT TOOL INOLDER PATIENTS WITH HEMATOLOGICAL MALIGNANCIES THATSHOWS MORTALITY PREDICTION CAPACITIES
OUTCOME OF PATIENTS WITH EXTRAMEDULLARY PLA-SMACYTOMAS (EMPS) INCLUDED IN A PHASE III PETHEMA/GEMSTUDYOF INDUCTION THERAPY PRIORAUTOLOGOUS STEM CELLTRANSPLANTATION (ASCT) IN MULTIPLE MYELOMA (MM)
RELATIONSHIP OF SERUM LEVELS OF SELECTED BIOLOGICAL IN-DICATORS AND CYTOGENETIC ABNORMALITIES IN MULTIPLEMYELOMA
INFLUENCE OF CRBN, IKZF1, AND IKZF3 EXPRESSION ONOUTCOME IN LENALIDOMIDE TREATED NEWLY DIAGNOSEDMULTIPLE MYELOMAPATIENTS
RESPONSE AND EARLY RELAPSE ASSESSMENT IN MULTIPLEMYELOMA TREATED WITH BORTEZOMIB: ROLE OF HEAVY/LIGHT-CHAIN IMMUNEASSAY
RISK FACTORS OF DEVELOPING SYMPTOMATIC MYELOMA FROMMGUS: ANALYSIS IN OUR HOSPITAL
DIFFUSIONWEIGHTEDWHOLE BODYMRI FOR EARLYEVALUATIONOF RESPONSE IN MULTIPLE MYELOMA
MYELOMABONE LESIONSONWHOLE-BODYDIFFUSION-WEIGHTEDMAGNETIC RESONANCE IMAGING AT 3.0 T: CHARACTERIZATIONAND COMPARISON OF APPARENT DIFFUSION COEFFICIENT ANDB1000 VALUE ON 2 DIFFERENT MRI PLATFORMS OF THE SAMEVENDOR
RENAL FUNCTION AND AGE AT PRESENTATION AND SERUM FREELIGHT CHAIN RESPONSE AT POST-INDUCTION PREDICT RENALOUTCOME
PREVALENCE OF OLIGOCLONAL BANDS IN MULTIPLE MYELOMAPATIENTS WHO ACHIEVED AT LEAST VERY GOOD PARTIALRESPONSE AFTER TREATMENT WITH STANDARD OR HIGH DOSECHEMOTHERAPY- FINALANALYSIS
DETECTING EARLY RELAPSE IN MULTIPLE MYELOMA (MM) AFTERASCT: USEFULNESS OF IMMUNEASSAYS
ABSOLUTE LYMPHOCYTE COUNT AS A PROGNOSTIC MARKER INNEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED INTHE ERAOF NOVELAGENTS
H. Takamatsu
J. de la Rubia
R. Jiménez
P. Pusciznova
J. Krönke
M. AndradeCampos
M. Itagaki
G. Barilà
S. Pans
P. Yadav
L. Soares VieiraDa Silva
M. AndradeCampos
C. Suriu
PO-031
PO-032
PO-033
PO-034
PO-035
PO-036
PO-037
PO-038
PO-039
PO-040
PO-041
PO-042
PO-043
15TH INTERNATIONALMYELOMAWORKSHOP
4544
CAPILLARY ZONE ELECTROPHORESIS IS A VERY SENSITIVEMETHODFORDIAGNOSISANDMONITORINGOFMULTIPLECLONESOF MULTIPLE MYELOMA, OTHER PLASMA CELL DYSCRASIAS ANDLYMPHOPROLIFERATIVE DISORDERS
PROSPECTIVEASSESSMENTOFACOMORBIDITYANDFUNCTIONALGERIATRIC ASSESSMENT (CF-GA), INCLUDING THE REVISEDFREIBURG COMORBIDITY INDEX (RFCI) IN MM PATIENTS (PTS)
NOVEL PROGNOSTIC MODEL OF COMBINATION NEUTROPHIL-LYMPHOCYTERATIO, PLATELETCOUNT,ANDC-REACTIVE PROTEINMIGHT PREDICT PROGNOSIS OF PATIENTS WITH NEWLYDIAGNOSED MULTIPLE MYELOMA
PROGNOSTIC VALUE OF FLOW CYTOMETRIC ANTIGEN EX-PRESSION PATTERN ON BONE MARROW NEOPLASTIC PLASMACELLS FROM MULTIPLE MYELOMAPATIENTS
TRANSLOCATIONT(8;14) INMULTIPLEMYELOMADEFINESPATIENTSWITH VERY POOR PROGNOSIS – SINGLE CENTRE EXPERIENCE
IMWG ´03 VS ´14 DIAGNOSTIC CRITERIA FOR SYMPTOMATICMULTIPLE MYELOMA: WILLWE HAVE TO SOLVEAPROBLEM?
CLINICAL VALUE OF SERUM FREE LIGH CHAINASSAY INALGERIANNEWLY DIAGNOSED MULTIPLE MYELOMA UNDERGOING HIGHDOSE THERAPY
A CYTOF-BASED APPROACH TO DETECT MINIMAL RESIDUALDISEASE IN PATIENTS WITH MULTIPLE MYELOMA
FRAILTY BURDEN IS ASSOCIATED WITH SURVIVAL IN ELDERLYPATIENTS WITH DIAGNOSIS OF MULTIPLE MYELOMA
MYD88 L265PMUTATIONSARECORRELATEDWITH 6QDELETION INKOREAN PATIENTS WITH WALDENSTRÖM MACROGLOBULINEMIA
ALKALINE PHOSPHATASE (ALP) LEVELS IN MULTIPLE MYELOMA(MM) AND CANCER WITH BONE LESIONS: IS THERE ANYDIFFERENCE?
CENTRAL NERVOUS SYSTEM INFILTRATION BY PLASMA CELLS:RARE OCCURRENCE IN MULTIPLE MYELOMAPATIENTS
PRONGNOSTIC IMPLICATION OF CYTOGENETIC ABNOMALITIESFOR NEWLYDIAGNOSEDMULIPLE MYELOMA IN YOUNG PATIENTS:TUNISIAN MONOCENTER EXPERIENCE
HIGH SERUM LACTATE DEHYDROGENASE LEVEL USED AS APROGNOSTIC FACTOR IN MULTIPLE MYELOMA
P.P. Kotoucek
A. Zober
D.S. Kim
Y. Meddour
T. Pika
S. Cerdá
Y. Meddour
A. Ghosh
N. Schütz
J.A. Kim
O. Annibali
A. Jorge
M. Zarrouk
D. Stoumbos
PO-073
PO-074
PO-075
PO-076
PO-077
PO-078
PO-079
PO-080
PO-081
PO-082
PO-083
PO-084
PO-085
PO-086
UTILITYOFTHEHEAVY/LIGHTCHAINASSAY INTHEEVALUATIONOFCOMPLETE RESPONSE TO THERAPY IN MULTIPLE MYELOMAPATIENTS
MULTIPLE MYELOMA AS A SECOND PRIMARY MALIGNANCY; ONEFOURTH OF PATIENTS HAD PRIOR HISTORY OF OTHER MA-LIGNANCES
THE IMPACT OF DIALYSIS-DEPENDENT ACUTE KIDNEY INJURY ONMORTALITY IN MYELOMA: FINDINGS FROM ENGLAND HOSPITALEPISODE STATISTICS DATA
EXPIRATION: INSPIRATION RATIO AS A PROGNOSTIC FACTOR INSYSTEMICALAMYLOIDOSIS
BASELINE F-18 FDGPETUPTAKEOFBONEMARROWASASURVIVALPREDICTOR IN PATIENTS WITH MULTIPLE MYELOMA
INFLUENCE OF KIDNEY HISTOLOGY ON PROGNOSIS IN MULTIPLEMYELOMA
THE CLINICAL SIGNIFICANCE OF DECREASING CD138 POSITIVEMYELOMACELLS IN BONE MARROW
A SINGLE CENTRE RETROSPECTIVE ANALYSIS OF DIAGNOSTICFLUORESCENCE IN SITU HYBRIDISATION REVEALS DISTINCTGROUPS OF CYTOGENETIC ABNORMALITIES, WHICH AFFECTEARLY SURVIVAL OF NEWMYELOMADIAGNOSIS
REVEALING GENOMIC PROFILE THAT UNDERLIES TROPISM OFMYELOMACELLS USINGWHOLE EXOME SEQUENCING
COMPARISON OF BONE MARROWASPIRATE AND BONE MARROWBIOPSY IN THE WORKUP OF PATIENTS WITH MULTIPLE MYELOMA
CHARACTERISTICS OF MYELOMA (MM) PATIENTS (PTS) WITHCENTRAL NERVOUS SYSTEM (CNS) INVOLVEMENT
HIGHEXPRESSIONOFAF1Q ISANADVERSEPROGNOSTIC FACTORIN MULTIPLE MYELOMA PATIENTS TREATED WITH AUTOLOGOUSSTEM CELL TRANSPLANTATION
EXPRESSION OF MTH1 IN MULTIPLE MYELOMA AND ITS RELA-TIONSHIP WITH THERAPEUTIC RESPONSE
CAST NEPHROPATHY VS ACUTE TUBULAR NECROSIS IN NEWLYDIAGNOSED MULTIPLE MYELOMA: ACOMPARATIVE STUDY
COMPARISON OF WHOLE-BODY LOW-DOSE COMPUTED TO-MOGRAPHYAND CONVENTIONAL RADIOGRAPHY IN THE STAGINGOF MULTIPLE MYELOMA
THE SIGNIFICANCE OF HEVYLITE TEST FOR DETERMINATION OFPROGNOSIS IN PATIENTS WITH ASYMPTOMATIC MULTIPLEMYELOMA - THE RESULTS OFANEW CMG PROJECT
J. Batini
N. Nishimura
M. Cook
W.K. Jeong
E. Lee
R. Bergner
M. Ikeda
I. Walker
S.S. Yoon
J. Dallemagne
T.A. Richards
S. Hagiwara
H. Zhou
I. Jaffer Sathick
H. Plonkova
V. Maisnar
PO-057
PO-058
PO-059
PO-060
PO-061
PO-062
PO-063
PO-064
PO-065
PO-066
PO-067
PO-068
PO-069
PO-070
PO-071
PO-072
4746
15TH INTERNATIONALMYELOMAWORKSHOP Auditorium Parco della Musica
SEPTEMBER 23-26, 2015
FRONTLINE THERAPY FOR MULTIPLE MYELOMA (MM) IN REAL-WORLD CLINICAL PRACTICE: RESULTS FROM THE THIRD INTERIMANALYSIS OF THE MULTINATIONAL, NON-INTERVENTIONAL, OB-SERVATIONAL EMMOS STUDY
CENTRAL NERVOUS SYSTEM INVOLVEMENT BY MULTIPLEMYELOMA:AMULTI-INSTITUTIONALRETROSPECTIVESTUDYOF 172PATIENTS
IMPROVED TUMOR RESPONSE AND SURVIVAL OUTCOMES WITHPOST-TRANSPLANT BORTEZOMIB (BTZ) CONSOLIDATION VERSUSOBSERVATION (OBS)ALONE IN PATIENTSWITHNEWLYDIAGNOSEDMULTIPLEMYELOMA (MM): RESULTS FROMARANDOMIZED, OPEN-LABEL, MULTICENTER, PARALLEL-GROUP PHASE 2 STUDY
CONTINUOUS TREATMENT WITH LENALIDOMIDE AND LOW-DOSEDEXAMETHASONE FOR PATIENTS WITH TRANSPLANT-INELIGIBLENEWLY DIAGNOSED MULTIPLE MYELOMA IN THE FIRST TRIAL:IMPACT OFAGE
IMPROVEMENT OF QUALITY OF RESPONSE AFTER ADDITIONALTHERAPYBEFOREAUTOLOGOUSSTEMCELLTRANSPLANT IS NOTTRANSLATED IN IMPROVEMENT OF GLOBAL OUTCOME OFMULTIPLE MYELOMAPATIENTS
EFFECTOF HIGH DOSEMELPHALANADMINISTRATION SCHEDULE:COMPARISON BETWEEN 1-DAY AND 2-DAY DOSE FOR MYELOMACONDITIONING REGIMEN
A2-STAGE PHASE II STUDYOF PANOBINOSTATCONSOLIDATION INMYELOMA PATIENTS WITH < CR FOLLOWING HIGH-DOSE CHE-MOTHERAPY (HDT) CONDITIONEDAUTOLOGOUSSTEMCELLTRAN-SPLANTATION (ASCT)
LEOPARD: A PHASE II STUDY OF POST AUTOLOGOUS STEM CELLTRANSPLANTATION (ASCT) MAINTENANCE LENALIDOMIDE ANDPREDNISOLONE FOR MYELOMA (MM), INCORPORATING MINIMALRESIDUAL DISEASE (MRD) ASSESSMENTS
FAVORABLE LONG-TERM SURVIVAL OF PATIENTS WITH MULTIPLEMYELOMA USING A FRONTLINE TANDEM APPROACH WITH AU-TOLOGOUS AND NONMYELOABLATIVE ALLOGENEIC TRAN-SPLANTATION
UPDATEDOVERALLSURVIVAL (OS)ANALYSISOFTHE FIRSTSTUDY:LENALIDOMIDE PLUS LOW-DOSE DEXAMETHASONE (RD)CONTINUOUS VS MELPHALAN, PREDNISONE, AND THALIDOMIDE(MPT) IN PATIENTS (PTS) WITH NEWLY DIAGNOSED MULTIPLEMYELOMA (NDMM)
HEAVY/LIGHT CHAIN ASSAYS IDENTIFY MONOCLONAL INTACT IM-MUNOGLOBULIN IN ‘LIGHT CHAIN ONLY’ PATIENTS
M. Mohty
A. Jurczyszyn
O. Sezer
C. Hulin
A. Natale
P. Lawasut
A. Kalff
A. Kalff
I. Ahmad
T. Facon
H. Ludwig
PO-087
PO-088
PO-089
PO-090
PO-091
PO-092
PO-093
PO-094
PO-095
PO-096
PO-097
PRETRANSPLANT INDUCTION WITH VTD (BORTEZOMIB/THALIDOMIDE /DEXAMETHASONE) SIGNIFICANTLY IMPROVES PFS:LONG-TERMRESULTSOFTHERANDOMIZEDPHASE3PETHEMA/GEMSTUDY
THEQUADRUPLETKCRD (CARFILZOMIB, CYCLOPHOSPHAMIDE, LE-NALIDOMIDE, AND DEXAMETHASONE) IS SAFE AND WELLTOLERATED AS INDUCTION THERAPY FOR NEWLY DIAGNOSED,TRANSPLANT ELIGIBLE, MYELOMAPATIENTS
INDUCTION REGIMENS FOR AUTOLOGOUS TRANSPLANT (AHCT)ELIGIBLE MYELOMA (MM) PATIENTS (PTS) – DOUBLETS ORTRIPLETSANDWHICH TRIPLET?
MYELOMACANADARESEARCH NETWORK (MCRN) 001 TRIALWITHINTRAVENOUS (IV) BUSULFAN + MELPHALAN (BUMEL) ASENHANCED CONDITIONING, FOLLOWED BY LENALIDOMIDE (LEN)MAINTENANCE IN NEWLY DIAGNOSED MULTIPLE MYELOMA (MM)PATIENTS (PTS): FIRST RESULTS OF MINIMAL RESIDUAL DISEASE(MRD) AND HEVYLITE(TM) CHAIN (HLC) ASSAYS AT DAY 100 POSTAUTOLOGOUS STEM CELL TRANSPLANT (ASCT)
IMMUNOHISTOCHEMICAL (IHC) BIOMARKERS ASSOCIATED WITHRESPONSEANDSURVIVALFOLLOWING LENALIDOMIDEANDPRED-NISOLONE MAINTENANCE POST-ASCT IN PATIENTS WITH MM: ANEXPLORATORY, HYPOTHESIS GENERATING SUB-STUDY OF THELEOPARD TRIAL
IMPACT OF COMPLETE RESPONSE ON PROGRESSION-FREESURVIVAL AND OVERALL SURVIVAL IN NEWLY DIAGNOSEDMYELOMA PATIENTS TREATED WITH AUTOLOGOUS STEM CELLTRANSPLANTATION OR CONVENTIONAL CHEMOTHERAPY:RESULTS OFAPOOLEDANALYSIS OF 5 PHASE III TRIALS
CONTINUOUS TREATMENT IMPROVES SURVIVAL OF NEWLYDIAGNOSEDMULTIPLEMYELOMAPATIENTSACHIEVINGCOMPLETERESPONSE: DATAFROM5PHASE III TRIALS INCLUDINGYOUNGANDELDERLY PATIENTS
THETREATMENT (TX) OF PATIENTS (PTS)WITHNEWLYDIAGNOSEDMULTIPLE MYELOMA (NDMM) INELIGIBLE FOR TRANSPLANT: A SY-STEMATIC LITERATURE REVIEWAND NETWORK META-ANALYSIS
MULTIPLE MYELOMA PATIENTS WITH UNMEASURABLE DISEASEBENEFIT LESS FROM BORTEZOMIB-BASED REGIMENS
IMPACT OF RESPONSE IN PATIENTS (PTS) WITH STEM CELLTRANSPLANT (SCT)-INELIGIBLE NEWLY DIAGNOSED MULTIPLEMYELOMA (NDMM) TREATEDWITH CONTINUOUS LENALIDOMIDE +LOW-DOSE DEXAMETHASONE (RD) IN THE FIRST TRIAL
L. Rosiñol
C. Pawlyn
P. Hari
D. Reece
A. Kalff
R. Mina
C. Cerrato
K. Weisel
X. Qin
N. Bahlis
BP-011
BP-012
BP-013
BP-014
BP-015
BP-016
BP-017
BP-018
BP-019
BP-020
2. Multiple Myeloma Therapy in Newly Diagnosed Patients including Transplantation
POSTER DISCUSSION SESSIONChairman: Andrzej J. Jakubowiak
POSTER SESSION
4948
15TH INTERNATIONALMYELOMAWORKSHOP Auditorium Parco della Musica
SEPTEMBER 23-26, 2015
TOTALMARROW IRRADIATION (TMI)WITHHELICALTOMOTHERAPYAND PERIPHERAL BLOOD PROGENITOR CELL RESCUE (PBPC)FOLLOWINGHIGH-DOSEMELPHALAN (MEL)ANDPBPCAS PARTOFTANDEM AUTOLOGOUS TRANSPLANT (TAT) FOR PATIENTS WITHMULTIPLE MYELOMA
APPRAISAL OF IGM KAPPA/IGM LAMBDA VARIATIONS USINGHEVYLITE® AFTER RITUXIMAB AS CONSOLIDATION THERAPY INPATIENTS WITH WALDENSTRÖM’S MACROGLOBULINEMIA
SAFETY AND EFFICACY OF FIRST-LINE TREATMENT WITH DO-XORUBICIN, CYCLOPHOSPHAMIDE, BORTEZOMIB, DEXA-METHASONE AND LENALIDOMIDE (ACVDL) IN NEWLY DIAGNOSEDMULTIPLE MYELOMAPATIENTS OFALLAGES
OUTCOME OF T(4;14) IN MULTIPLE MYELOMA – PRINCESSMARGARET CANCER CENTRE EXPERIENCE OVER THE LAST 10YEARS
AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) FORMULTIPLE MYELOMA (MM): PREDICTORS OF LONG TERMOUTCOME
LOW DOSE DEXAMETHASONE PLUS LENALIDOMIDE (LEN-DEXA)VERSUSTHALIDOMIDE (THAL-DEXA)AS INDUCTION THERAPY FORNEWLY DIAGNOSED MULTIPLE MYELOMA: A PHASE III,RANDOMIZED STUDY
LENALIDOMIDE MAINTENANCE CAUSES PERSISTENCE OFABNORMAL PROTEIN BANDS IN MULTIPLE MYELOMA PATIENTSAFTER INDUCTION WITH NEW DRUGS AND AUTOLOGOUS BONEMARROW TRANSPLANTATION
AUTOLOGOUS STEMCELLTRANSPLANTATION (ASCT) IN PATIENTSWITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) OVER 65YEARS
EARLY CLINICAL OUTCOMES AND LONG-TERM SURVIVAL IN MMPATIENTS UNDERGOING AUTOLOGOUS HSCT AFTER MELPHALAN200 MG/M2 CONDITIONING WITHOUT WEIGHT-BASED DOSE-AD-JUSTMENTARE UNAFFECTED BY BODYMASS INDEX
PROGNOSTIC FACTORS FOR OVERALL AND PROGRESSION-FREESURVIVAL IN PATIENTS WITH MULTIPLE MYELOMA UNDERGOINGSINGLEAUTO-SCT
OUTCOME AFTER AUTOLOGOUS STEM CELL TRANSPLANTATIONFORMYELOMAIN PATIENTS BEYOND 60, 65AND 70YEARSOFAGE:ARETROSPECTIVEANALYSIS FROM THE GERMAN REGISTRY FORSTEM CELL TRANSPLANTATION (DRST)
A MULTI-CENTRE REVIEW OF MOBILISATION STRATEGIES POSTUPFRONTVCD INDUCTION INMULTIPLEMYELOMA: ISG-CSFALONESUFFICIENT?
G. Somlo
J.R. Eveillard
K.T. Andersen
V. Kukreti
L. Kumar
L. Kumar
B. Gamberi
S. Cerdá
A. Roque
V.H. JimenezZepeda
M. Merz
C.C. Chua
PO-110
PO-111
PO-112
PO-113
PO-114
PO-115
PO-116
PO-117
PO-118
PO-119
PO-120
PO-121
BORTEZOMIB BASED THERAPIES AND HIGH CUT OFF FILTERDYALYSIS (HCO)ARE EFFECTIVE INMULTIPLEMYELOMAPATIENTSWITH END STAGE RENAL FAILURE
SUBCUTANEOUS BORTEZOMIB PLUS MELPHALAN ANDPREDNISONE (VMP) IN NON-TRANSPLANT ELIGIBLE NEWLYDIAGNOSED MULTIPLE MYELOMA (MM) PATIENTS: SPANISH EX-PERIENCE
SERUM FREE LIGHT CHAIN CHANGES OFFER A MORE ACCURATEASSESSMENT OF RESPONSE TO THERAPY THAN URINE BENCEJONES PROTEIN EXCRETION MEASUREMENTS IN MULTIPLEMYELOMA
EFFICACY OF NEW DRUGS AS TREATMENT BEFORE SINGLE ORTANDEM AUTOLOGOUS STEM CELL TRANSPLANTATION IN NEWLYDIAGNOSED MULTIPLE MYELOMAPATIENTS
CLINICALOUTCOMES IN PATIENTS (PTS)WITH NEWLYDIAGNOSEDMULTIPLE MYELOMA (NDMM) AND T(4;14) IN THE CONNECT MM®REGISTRY
A RANDOMIZED PHASE II STUDY OF STEM CELL MOBILIZATIONWITHCYCLOPHOSPHAMIDE +G-CSF VERSUSG-CSFALONEAFTERLENALIDOMIDE-BASED INDUCTION IN MULTIPLE MYELOMA
LONGTERMCRYOPRESERVEDAUTOLOGOUSBLOODSTEMCELLSFOR SALVAGE AUTOLOGOUS STEM CELL TRANSPLANTATION(ASCT) IN RELAPSED MULTIPLE MYELOMA (MM) PATIENTS
CONTINUOUS LENALIDOMIDE AND LOW-DOSE DEXAMETHASONEFOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSEDMULTIPLE MYELOMAAND RENAL IMPAIRMENT IN THE FIRST TRIAL
RECOMBINANT MAGE-A3 PROTEIN IMMUNOTHERAPY AND PE-RIPHERAL BLOOD LYMPHOCYTE (PBL) RECONSTITUTION INDUCESTRONG ANTIGEN-SPECIFIC HUMORAL AND CELLULAR IMMUNERESPONSES IN PATIENTSUNDERGOINGAUTOLOGOUSSTEMCELLTRANSPLANTATION (ASCT) FOR CONSOLIDATION OF MULTIPLEMYELOMA (MM)
LONG-TERM EFFICACY OF SEQUENTIAL VINCRISTINE,ADRIAMYCIN, AND DEXAMETHASONE (VAD) AND BORTEZOMIB,THALIDOMIDE, AND DEXAMETHASONE (VTD) AS INDUCTION CHE-MOTHERAPY FOLLOWED BY HIGH-DOSE MELPHALAN WITH AU-TOLOGOUS STEM CELL TRANSPLANTATION (AUTO-SCT) ANDBORTEZOMIB CONSOLIDATION: A FOLLOW-UP STUDY OF KMM51
IMPACT OF ANTI-MYELOMA IDUCTION TREATMENT AND OTHERPREDICTIVE FACTORSONSTEMCELLHARVESTING, IN THENOVEL-AGENT ERA
CYCLOPHOSPHAMIDE, BORTEZOMIB, AND DEXAMETHASONE(CYBORD) INDUCTION: IMPACTON RESPONSE RATEAND MDR NE-GATIVITY FOR PATIENTS WITH MULTIPLE MYELOMAUNDERGOINGSINGLEAUTO-SCT
A. Gozzetti
F. De Arriba
T. Dejoie
S. Grammatico
J.J. Shah
R. Silvennoinen
N. Areethamsiri-kul
M. Dimopoulos
N. Lendvai
J. Shin
C. Lalayanni
V.H. JimenezZepeda
PO-098
PO-099
PO-100
PO-101
PO-102
PO-103
PO-104
PO-105
PO-106
PO-107
PO-108
PO-109
5150
15TH INTERNATIONALMYELOMAWORKSHOP Auditorium Parco della Musica
SEPTEMBER 23-26, 2015
THE TREATMENT STRATEGIES IN PATIENTS WITH PARTIALRESPONSE TO HIGH-DOSE CHEMOTHERAPYANDASCT
ENGRAFTMENT SYNDROME DURING AUTO HSCT IN PLASMACELLDISORDERS: RETROSPECTIVE ANALYSIS OF CONSECUTIVECASES FROMATERTIARY CARE CENTRE
RETROSPECTIVEANALYSIS OF THE IMPACTOF KIDNEY FUNCTIONON THE OUTCOMES OF FIRST AUTOGRAFTS FOR DE NOVOMYELOMAPATIENTS IN THE ERAOF NOVELAGENTS
COMPARISONOFTHEPERFORMANCEOFTHENEWLYDEVELOPEDIGG HEAVY CHAIN/LIGHT CHAIN IMMUNOASSAYS WITH SERUMPROTEIN ELECTROPHORESIS FOR MONITORING IGG MULTIPLEMYELOMAPATIENTS
IDENTIFICATION OF PREDICTOR FACTORS FOR EARLY RELAPSE(ER) IN PATIENTS WITH MM UNDERGOING SINGLEAUTO-SCT
PHASE 1 STUDYOFELOTUZUMAB (ELO) IN COMBINATIONWITH LE-NALIDOMIDE/DEXAMETHASONE (LEN/DEX) IN JAPANESE PATIENTS(PTS) WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA(RRMM) AND LONG-TERM FOLLOW-UP
SUBCUTANEOUS ADMINISTRATION OF BORTEZOMIB SIGNI-FICANTLY DECREASEDAND DELAYED THE DEVELOPMENT OF PE-RIPHERAL NEUROPATHY IN PATIENTS WITH NEWLY DIAGNOSEDMULTIPLE MYELOMA
MELPHALAN 140MG/M"2" SIGNIFICANTLY REDUCES 5 YEAR PRO-GRESSION FREE SURVIVAL IN MULTIPLE MYELOMA PATIENTSRECEIVING A PERIPHERAL BLOOD AUTOLOGOUS STEM CELLTRANSPLANT COMPAREDWITH MELPHALAN 200MG/M"2"
REGISTRY BASED RETROSPECTIVEANALYSIS OF BENDAMUSTINECONDITIONED SECOND AUTOLOGOUS HEMATOPOIETIC STEMCELL TRANSPLANTS FOR RELAPSED MYELOMA
THE EMPEROR IS NAKED: THE QUALITY OF RESPONSE TO FIRST-LINE THERAPY IS NOT RELATED TO SURVIVAL IN MULTIPLEMYELOMA (MM) PATIENTS
PHASE 2 STUDYUSING INTRAVENOUSBUSULFANANDMELPHALANCONDITIONING REGIMEN FOR AUTOLOGOUS STEM CELL TRAN-SPLANTATION IN PATIENTS WITH MULTIPLE MYELOMA: INTERIMANALYSIS (KMM150)
INCREASED INCIDENCE OF SYMPTOMATIC POSTURAL HY-POTENSION INMULTIPLEMYELOMAPATIENTSTREATEDWITHSUB-CUTANEOUS BORTEZOMIB
HEALTH RESOURCE UTILIZATION WITH CONTINUOUS LENA-LIDOMIDE TREATMENT (TX) IN ELDERLY PATIENTS (PTS) WITHNEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM)
S.K. Park
R. Pramanik
L. Floro
O. Berlanga
V.H. JimenezZepeda
T. Chou
Y. Xu
C. Attwood
L. Floro
I. Hardan
J.J. Lee
S. Ahmed
K. Weisel
PO-136
PO-137
PO-138
PO-139
PO-140
PO-141
PO-142
PO-143
PO-144
PO-145
PO-146
PO-147
PO-148
SKIN INVOLVEMENT BY MULTIPLE MYELOMA: A MULTI-INSTI-TUTIONAL RETROSPECTIVE STUDY OF 53 PATIENTS
A RESPONSE ADAPTED APPROACH TO INDUCTION TREATMENTYIELDS ACCEPTABLE OUTCOME IN PATIENTS WITH MULTIPLEMYELOMA (MM) UNDERGOING AUTOLOGOUS STEM CELL TRAN-SPLANTATION (ASCT)
VCD, VD AND VMP IN FRONT LINE TREATMENT: OUTCOMES FROMTHAI MYELOMA WORKING GROUP – PATIENT ASSISTANCEPROGRAM (TMWG-PAP)
NUMBEROFCD34 +CELLSCOLLECTEDBETWEENTWODIFFERENTMOBILIZATIONSCHEDULES INMULTIPLEMYELOMAPATIENTSWITHCTD INDUCTION AND CANDIDATES FOR AUTOLOGOUSTRANSPLANT OF HEMATOPOIETIC PROGENITOR CELLS
PROGRESSION-FREE SURVIVALFOLLOWINGAUTOLOGOUSTRAN-SPLANTATION FORMULTIPLEMYELOMAIS NOTCOMPROMISEDBYTHE USE OF DOSE-ADJUSTED MELPHALAN
SUCCESSFULASSESSMENTANDEDUCATIONAL INTERVENTIONOFGUIDELINE-BASED APPROACHES FOR THE MANAGEMENT OFMULTIPLE MYELOMA
THE EFFICACY AND SAFETY OF HIGH DOSE MELPHARAN PLUSBORTEZOMIB FOLLOWED BY AUTO PBSCT IN ELDERLY MULTIPLEMYELOMAPATIENTS
COMPARISONOFTHEPERFORMANCEOFTHENEWLYDEVELOPEDIGA HEAVY CHAIN/LIGHT CHAIN IMMUNOASSAYS WITH SERUMPROTEIN ELECTROPHORESIS AND NEPHELOMETRIC TOTAL IGAMEASUREMENTS FOR MONITORING IGA MULTIPLE MYELOMAPATIENTS
PRE TRANSPLANT ACHIEVEMENT OF VERY GOOD PARTIALRESPONSE RESULTS IN IMPROVED SURVIVAL IN MYELOMA
EARLY PROGRESSION (WITHIN 12 MONTHS) AFTER AUTOLOGOUSSTEM-CELL TRANSPLANTATION IN PATIENTS WITH MULTIPLEMYELOMA
CLINICAL FEATURES AND OUTCOMES AFTER AUTO-SCT INPATIENTS WITH MULTIPLE MYELOMAAND RENAL IMPAIRMENT
STEM CELL MOBILIZATION AND AUTOLOGOUS STEM CELL TRAN-SPLANTATION AFTER PRETREATMENT CONSISTING OF BEN-DAMUSTINE, PREDNISONEANDBORTEZOMIB (BPV) IN 35 PATIENTSWITH NEWLY DIAGNOSED/UNTREATED MULTIPLE MYELOMA
SERUM FREE LIGHT CHAIN ASSAYS, NOT TOTAL LIGHT CHAINASSAYS, ARE THE STANDARD OF CARE IN THE ASSESSMENT OFMONOCLONALGAMMOPATHIES
HEAVY CHAIN/ LIGHT CHAIN IMMUNOASSAYS FOR MONITORINGOLIGOSECRETORYMULTIPLE MYELOMAPATIENTS
A. Jurczyszyn
G.L. Shah
P. Lawasut
E. de QueirozCrusoe
J. Sangha
E.S. Van Laar
N. Takezako
O. Berlanga
O.S. Yeu
S.H. Lim
H. Ryu
W. Poenisch
V. Hungria
O. Berlanga
PO-122
PO-123
PO-124
PO-125
PO-126
PO-127
PO-128
PO-129
PO-130
PO-131
PO-132
PO-133
PO-134
PO-135
5352
15TH INTERNATIONALMYELOMAWORKSHOP Auditorium Parco della Musica
SEPTEMBER 23-26, 2015
A PROSPECTIVE PHASE II TRIAL OF LENALIDOMIDE AND DEXA-METHASONE (LEN-DEX) IN POEMS SYNDROME
AUTOLOGOUS STEMCELLTRANSPLANTATION (ASCT) IN PATIENTSWITH POEMS SYNDROME RESULTS IN DURABLE SYMPTOMATICDISEASE CONTROL: A RETROSPECTIVE STUDY OF THE PLASMACELL DISORDER SUB-COMMITTEE OF THE CHRONIC MALI-GNANCIES WORKING PARTY OF THE EBMT
SAFETY AND EFFICACY OF CARFILZOMIB (CFZ) IN PREVIOUSLY-TREATED SYSTEMIC LIGHT-CHAIN (AL) AMYLOIDOSIS
A RANDOMIZED PHASE III TRIAL OF MELPHALAN AND DEXA-METHASONE (MDEX) VERSUS BORTEZOMIB, MELPHALANAND DE-XAMETHASONE (BMDEX) FOR UNTREATED PATIENTS WITH ALAMYLOIDOSIS
INTERIMANALYSIS OFALCHEMY–APROSPECTIVE STUDYOF 1000PATIENTS WITH SYSTEMICALAMYLOIDOSIS
PHASE 3 STUDYOF THE ORALPROTEASOME INHIBITOR IXAZOMIBFORRELAPSED/REFRACTORYALAMYLOIDOSIS: TOURMALINE-AL1
ANALYSIS OF SECOND PRIMARYMALIGNANCIES (SPMS) IN CALGB(ALLIANCE)/ECOG/BMT CTN 100104
SYSTEMATIC CLASSIFICATION OF DEATH CAUSES IN MULTIPLEMYELOMAPATIENTS TREATEDWITH HIGH-DOSE THERAPY
COMBINING EFFICACY AND TOXICITY EFFECT SIZES FROMRANDOMIZED CLINICAL TRIALS (RCTS) INTO AN INTERPRETABLEQUALITY-ADJUSTED EFFECT SIZE ESTIMATE IN PATIENTS WITHMULTIPLE MYELOMA (MM)
IMPACTOFNOVELTHERAPIESONMULTIPLEMYELOMASURVIVAL–CURRENTAND FUTURE OUTCOMES
GUIDELINES FOR THE CORRECT DETERMINATION OF SECONDPRIMARYMALIGNANCIES IN MYELOMATRIALS
LEVELS OF DISCORDANCE BETWEEN PATIENTS’AND PHYSICIANS’PERCEPTIONS OF PATIENTS’ HEALTH-RELATED QUALITY OF LIFE(HRQOL) IN RELAPSED/REFRACTORYMULTIPLEMYELOMA(RRMM)– ACROSS-CULTURAL PERSPECTIVE
ORTHOTOPICHEARTTRANSPLANTFACILITATEDAUTOLOGOUSHE-MATOPOIETIC STEMCELLTRANSPLANTATION IN LIGHT-CHAINAMY-LOIDOSIS
A. Jaccard
G. Cook
A.D. Cohen
E. Kastritis
A. Wechalekar
G. Merlini
S.A. Holstein
E.M. Haas
B. Major
A. Drawid
J. Jones
X. Leleu
R.T. Kamble
BP-021
BP-022
BP-023
BP-024
BP-025
BP-026
BP-027
BP-028
BP-029
BP-030
PO-164
PO-165
PO-166
SUCCESFUL STEM CELL COLLECTION IN NEWLY DIAGNOSEDMULTIPLE MYELOMA (NDMM) PATIENTS OVER 65 YEARS OLD
AUTOLOGOUS STEM CELLCOLLECTIONAFTER BIOSIMILAR G-CSF(ZARZIO®) COMPARED TO ORIGINAL G-CSF (NEUPOGEN®) INMULTIPLE MYELOMAPATIENTS
SUCCESSFUL TREATMENT OF PATIENTS WITH NEWLYDIAGNOSED/UNTREATED LIGHT CHAIN MULTIPLE MYELOMAWITHA COMBINATION OF BENDAMUSTINE; PREDNISONE ANDBORTEZOMIB (BPV)
COMPARISON OF THE CLINICAL SENSITIVITY OF TWO FREE LIGHTCHAINASSAYS INACOHORTOF LIGHTCHAIN MULTIPLE MYELOMAPATIENTS
FRONTLINE TREATMENT SCHEME VTD (BORTEZOMIB/ THA-LIDOMIDE/DEXAMETHASONE) IN PATIENTS WITH MULTIPLEMYELOMATRANSPLANT CANDIDATESAT OUR CENTER
AUTOLOGOUS STEM CELL TRANSPLANTATION FORALAMYLOIDOSIS
DAY 4 PERIPHERALBLOOD STEM CELLCOLLECTION IN MYELOMAPATIENTS IS FEASIBLEANDAND COST-EFFECTIVE INAMAJORITYOF PATIENTS
EVALUATION OF THE NOVEL HEVYLITE® IGM KAPPA/IGM LAMBDAASSAYS IN WALDENSTRÖM’S MACROGLOBULINEMIA PATIENTSAFTER RITUXIMAB CONSOLIDATION THERAPY
THE EVOLVING ROLE OF STEM CELL TRANSPLANT IN MULTIPLEMYELOMA: A SINGLE INSTITUTION STUDY
PREDICTION OF POOR MOBILIZATION OF PERIPHERAL BLOODSTEM CELLS (PBSC) WITH G-CSF ALONE, IN MULTIPLE MYELOMA(MM) PATIENTS UNDERGOING AUTOLOGOUS TRANSPLANTATION:A PROSPECTIVE STUDY
STEM CELL TRANSPLANTATION FOR MULTIPLE MYELOMA: SINGLECENTER EXPERIENCE
BORTEZOMIB BASED REGIMEN IN YOUNG HIGH RISK MULTIPLEMYELOMA PATIENTS RELAPSED AFTER ALLOGENEIC STEM CELLTRANSPLANTATION: TWO CLINICAL CASES
AUTOLOGOUS STEM CELL TRANSPLANTATION AND PRIMARYSYSTEMIC LIGHT CHAIN (AL) AMYLOIDOSIS
FOUR PHASE 3 STUDIES OF THE ORAL PROTEASOME INHIBITOR(PI) IXAZOMIB FORMULTIPLEMYELOMAINTHENEWLY-DIAGNOSED,RELAPSED/REFRACTORY, AND MAINTENANCE SETTINGS:TOURMALINE-MM1, -MM2, -MM3, AND -MM4
CENTAURUS (JNJ5467414SMM2001):ARANDOMIZEDPHASE II TRIALTO EVALUATE THREE DARATUMUMAB (DARA) DOSE SCHEDULESIN SMOLDERING MULTIPLE MYELOMA (SMM)
C. Cecchini
J. Radocha
H. Mrachacz
T. Dejoie
R. GarciaSanchez
H.N. Song
E. Kaul
J.R. Eveillard
R. Ríos-Tamayo
R.R. Boya
Z. Bolaman
M. Quaresima
S.K. Toprak
J. San Miguel
C.C. Hofmeister
PO-149
PO-150
PO-151
PO-152
PO-153
PO-154
PO-155
PO-156
PO-157
PO-158
PO-159
PO-160
PO-161
PO-162
PO-163
3. Epidemiology, QoL, Toxicities, and Other Plasma Cell Dyscrasias
POSTER DISCUSSION SESSIONChairman: Raymond L. Comenzo
POSTER SESSION
5554
15TH INTERNATIONALMYELOMAWORKSHOP Auditorium Parco della Musica
SEPTEMBER 23-26, 2015
CARDIAC AMYLOID IMAGING WITH 18F-FLORBETABEN POSITRONEMISSION TOMOGRAPHY: A PILOT STUDY
DEVELOPMENT OF MONOCLONAL GAMMOPATHY OF UNDE-TERMINED SIGNIFICANCEAFTER KIDNEY TRANSPLANT
RISK OF INVASIVE FUNGAL INFECTIONS IN PATIENTS WITHMULTIPLE MYELOMA RECEIVING NOVEL THERAPIES: A SINGLEASIAN MEDICAL CENTER STUDY
POSSIBLE NEWDISEASE ENTITYOFALAMYLOIDOSIS INDUCED BYDEPOSITION OF IGLC2
CONTINUED IMPROVEMENT IN OVERALL SURVIVAL IN ELDERLYMULTIPLE MYELOMAPATIENTSAFTER 2008; APOPULATION BASEDSTUDY FROM THE DANISH MULTIPLE MYELOMAREGISTRY
IS THROMBOPROPHYLAXIS NECESSARY FOR MYELOMAPATIENTS? A CLINICAL DILEMMAAND PROPOSAL OF A PRACTICALGUIDELINE
VIRALRESPIRATORYTRACT INFECTION IN PATIENTSWITH PLASMACELL DISORDER IN CURRENT STANDARD TREATMENT
REAL WORLD MANAGEMENT OF MULTIPLE MYELOMA: INITIALRESULTS FROM THE AUSTRALIA AND NEW ZEALAND MYELOMAAND RELATED DISEASES REGISTRY
PATIENT POPULATION WITH MULTIPLE MYELOMA ANDTRANSITIONSACROSS LINESOFTHERAPY INTHEUNITEDSTATES:AN EPIDEMIOLOGIC MODEL
UP-REGULATIONOFTNFRSF13ANDHMGB1 INWALDENSTROMMA-CROGLOBULINEMIA WITH OSTEOLYTIC BONE LESION
HEAVY/LIGHT CHAIN IMMUNOPARESIS IDENTIFIES SYSTEMIC ALAMYLOIDOSIS PATIENTS WITH POOR SURVIVAL OUTCOMES
ADHERENCE TO ORAL IMMUNOMODULATORY THERAPY AT ACOMMUNITY CANCER CENTER
PROGNOSTIC VALUE OF HEVYLITE CHAIN IN A POPULATIONCOHORT OF MONOCLONAL GAMMOPATHY OF UNCERTAIN SI-GNIFICANCE
PREVALENCE OF THE ALTERATION OF THE RATIO KAPPA/LAMBDABY FREELITE® IN BLOODDONORSOVER FORTYYEARSOFAGEATSANTACASAOF SÃO PAULO: PRELIMINARYANALYSIS
EXPECTANCY OF LIFE AND INCIDENCE RATE OF NEWLYDIAGNOSEDMULTIPLEMYELOMA(NDMM) PATIENTS. 15 YEARSRE-TROSPECTIVEANALYSIS
CYCLOPHOSPHAMIDE, BORTEZOMIB, AND DEXAMETHASONE(CYBORD) FORTHETREATMENTOFALAMYLOIDOSIS: EXPERIENCEATASINGLE INSTITUTION
P. Mollee
J.W. Tan
P. Hsu
E. Fujii
N. Abildgaard
A. Kato
M.Y. Lee
E. Moore
J. Cid Ruzafa
N. Sekiguchi
S. Sachchitha-nantham
A. Benyounes
A. García Mateo
M.M. Arruda
B. Ballina
V.H. JimenezZepeda
PO-182
PO-183
PO-184
PO-185
PO-186
PO-188
PO-189
PO-190
PO-191
PO-192
PO-193
PO-194
PO-195
PO-196
PO-197
PO-198
THE EFFECT OF BORTEZOMIB TREATMENT ON ANTIBODY TITERSAGAINST COMMON VIRALAND VACCINEANTIGENS
CONDITIONAL SURVIVAL ANALYSIS OF MULTIPLE MYELOMAPATIENTS: EXPERIENCE OF THE COMPREHENSIVE CANCERCENTER FREIBURG (CCCF) UNIVERSITY MEDICAL CENTERFREIBURG
HEAVY CHAIN DISEASES: ARETROSPECTIVE STUDY
LESS THAN 30% OF RELAPSED LIGHT CHAIN (AL) AMYLOIDOSISPATIENTS WITH PROGRESSIVE DISEASE REQUIRING THERAPYHAVE MEASURABLE SERUM FREE LIGHT CHAIN DIFFERENCES(DFLC): BETTER CRITERIA TO DEFINE HEMATOLOGIC PRO-GRESSIONARE NEEDED
SURVIVAL ANALYSIS IN NEWLY DIAGNOSED MULTIPLE MYELOMAPATIENTS IN THE UNITED STATES MEDICARE DATABASE
CLINICAL PREVALENCE OF MONOCLONAL GAMMOPATHY OF UN-DETERMINED SIGNIFICANCE (MGUS) IN THE UNITED STATES:ESTIMATING THE BURDEN ON HEALTH CARE
CLINICAL CHARACTERISTICS, OUTCOMES AND PREDICTORS OFPROGRESSION TOMULTIPLE MYELOMA (MM) IN 61 PATIENTSWITHSOLITARY PLASMACYTOMA
VALIDATION OF THE 2012 HEMATOLOGIC RESPONSE CRITERIA INLIGHT CHAIN AMYLOIDOSIS USING THE CENTER FOR INTER-NATIONAL BLOOD AND MARROW TRANSPLANT (CIBMTR)DATABASE
THE INCIDENCEANDCLINICALFEATURESOFHBVREACTIVATION INMULTIPLE MYELOMA PATIENTS TREATED WITH NOVEL AGENTSAND/ORASCT: ARETROSPECTIVE MULTICENTER STUDY IN JAPAN
COLD AGGLUTININ DISEASE IS A PHENOTYPICALLY DISTINCTCLONAL B-CELL DISORDER
THE PRESENCE OF MYD88 L265P IN NON-IGM LYMPHOPLA-SMACYTIC LYMPHOMA: IMPLICATIONS FOR DIAGNOSIS ANDTHERAPY
EVALUATING THE USE OF MULTIPARAMETRIC FLOW CYTOMETRYIN ESTABLISHING THE PRESENCE OFMINIMALRESIDUALDISEASEIN SYSTEMICALAMYLOIDOSIS: AREPORT OF EIGHT PATIENTS
HOSPITALIZATION RATES FOR NEWLY DIAGNOSED MULTIPLEMYELOMAPATIENTS IN THE UNITED STATESMEDICARE DATABASE
LECT2AMYLOIDOSIS: NOT JUSTAHISPANIC DISEASE
PROGRESSIVE INNOVATION IN ONCOLOGY: VALUING OUTCOMESBEYOND SURVIVAL
K. Celotto
J.M. Wal-dschmidt
C. ChapuisCellierH. Landau
A.A. Yusuf
R.S. Go
E.E. Manasanch
A. D’Souza
Y. Tsukune
R. De Tute
R. De Tute
M. Coyne
A.A. Yusuf
J. Ramzy
C. Quinn
PO-167
PO-168
PO-169
PO-170
PO-171
PO-172
PO-173
PO-174
PO-175
PO-176
PO-177
PO-178
PO-179
PO-180
PO-181
5756
15TH INTERNATIONALMYELOMAWORKSHOP Auditorium Parco della Musica
SEPTEMBER 23-26, 2015
PRIMARY SYSTEMIC AMYLOIDOSIS ASSOCIATED WITH MULTIPLEMYELOMA. OUR EXPERIENCE
SECOND MALIGNANCIES AND MULTIPLE MYELOMA. A SINGLE-IN-STITUTION EXPERIENCE IN SPAIN
SCLEREDEMAASSOCIATED WITH MULTIPLE MYELOMA OR MGUS:TREATMENT REPORT OF FOUR CASES
SUBCUTANEOUS BORTEZOMIB-INDUCED PARALYTIC ILEUS INMULTIPLE MYELOMAPATIENTS
DISSEMINATED CRYPTOCOCCAL INFECTION IN AN IMMUNO-COMPETENT HOST MIMICKING PLASMA CELL DISORDER: A CASEREPORTAND LITERATURE REVIEW
POMALIDOMIDE AND DEXAMETHASONE ASSOCIATION IS ANEFFECTIVE SALVAGE THERAPY IN SECONDARY PLASMA CELLLEUKAEMIA (SPCL)
THE IMPORTANCE OF FUNDUS EXAMINATION FOR FEVERETIOLOGY INAPATIENTWITH MYELOMA
CASE STUDY: AN EXAMPLE OF MANUAL PLASMA EXCHANGE IN ACHALLENGING PATIENT WITH HYPERVISCOSITY SECONDARY TOWALDENSTROM'S MACROGLOBULINAEMIA
F. Almagro Torres
S. Cerdá
M. Krejci
G. Mele
M.B. Abid
G. Mele
Z. Bolaman
N. Shanmugana-than
PO-216
PO-217
PO-218
PO-219
PO-220
PO-221
PO-222
PO-223
A RETROSPECTIVE ANALYSIS AT THE PRINCESS MARGARETCANCER CENTRE OF THE INITIAL THERAPY OF AL AMYLOIDOSIS:CYBORD VERSUS OTHER REGIMENS
TREATMENT RESULTS OF VENOUS THROMBOEMBOLISM WITHDALTEPARIN IN PATIENTSWITHMULTIPLEMYELOMAUNDERGOINGANTI-MYELOMACHEMOTHERAPEUTICAGENTS
SUBCUTANEOUS IMMUNOGLOBULIN FOR TREATMENT OFSECONDARY HYPOGAMMAGLOBULINEMIA IN MULTIPLE MYELOMA
POEMS SYNDROME: A RETROSPECTIVE ANALYSIS OF CLINICOPA-THOLOGICAL PROFILE AND TREATMENT OUTCOMES OF 43 CON-SECUTIVE CASES FROMATERTIARY CANCER CENTRE IN INDIA
FOLLOWING THE GUIDELINES FOR REDUCING OSTEONECROSISOF THE JAW ASSOCIATED WITH BISPHOSPHONATE THERAPY INSYMPTOMATIC MULTIPLE MYELOMA - EXPERIENCE OFADISTRICTGENERAL HOSPITAL
SECONDARYMALIGNANCIES IN MULTIPLE MYELOMA
AUTOLOGOUS HCT IN ELDERLY MYELOMA PATIENTS, AHNCISINGLE INSTITUTION EXPERIENCE
BLEEDING DIATHESIS AND PROTHROMBOTIC TENDENCIES INPATIENTS WITH NEWLY DIAGNOSED SYSTEMIC LIGHT CHAINAMY-LOIDOSIS: IMPORTANT CLINICAL IMPLICATIONS
CZECH MYELOMA GROUP REGISTRY OF MONOCLONAL GAM-MOPATHIES
PLASMACELL LEUKEMIA. EXPERIENCE IN OUR CENTER
QUALITY OF LIFE IN MULTIPLE MYELOMA: VALIDATION OF THETURKISH VERSION OF THE QLQ-MY20 INSTRUMENT
THE VERIFICATION OF RENAL PROGNOSIS OFALAMYLOIDOSIS
FINDING THE MEANING OF LIFE OF PATIENTS WITH MULTIPLEMYELOMA CORRELATES WITH BETTER CONTROL OF THEIRDISEASE BY CHEMOTHERAPY
INCIDENCE OF NEUROPATHY IN PATIENTS TREATED WITHBORTEZOMIB SUBCUTANEOUS
MONOCLONALGAMMOPATHYOFRENALSIGNIFICANCE (MGRS).HE-MATOLOGICAL AND RENAL COMPLETE RESPONSE WITHBORTEZOMIB
SAFETY AND ADHESION WITH SUBCUTANEOUS BORTEZOMIBTREATMENT IN MULTIPLE MYELOMA
INCIDENCE OF PERIPHERAL NEUROPATHY IN CLINICAL PRACTICEIN MULTIPLE MYELOMAPATIENTS TREATEDWITH REGIMENSWITHSUBCUTANEOUSADMINISTRATION OF BORTEZOMIB
R. Kaedbey
C.K. Min
R. Ria
R. Pramanik
J. Page
C. Vadikoliou
E. Sahovic
S. Mahmood
V. Maisnar
F. Almagro Torres
O.G. Sevindik
Y. Yoshiki
P.P. Kotoucek
A. VicentCastelló
A. Alegre
F. Escalante
A. Garcia-Guiñon
PO-199
PO-200
PO-201
PO-202
PO-203
PO-204
PO-205
PO-206
PO-207
PO-208
PO-209
PO-210
PO-211
PO-212
PO-213
PO-214
PO-215
5958
15TH INTERNATIONALMYELOMAWORKSHOP Auditorium Parco della Musica
SEPTEMBER 23-26, 2015
TARGETING HEPARANASE TO INHIBIT MYELOMA CHEMORE-SISTANCE
EZH2 OVEREXPRESSION IN MYELOMA PATIENTS SHORTENSSURVIVALAND IN-VITRO DATASUPPORTSAPOTENTIAL NEWTARGETED TREATMENT STRATEGY
FILANESIB (ARRY-520) DEMONSTRATES POTENT AND RAPIDACTIVITY IN PRECLINICAL MODELS OF MM, DEPENDENT ON BCL-2FAMILY EXPRESSION, AND SYNERGISTIC WITH DEXAMETHASONEAND IMIDS
REVERSE SIGNALING VIA B7-H1/PD-1 INTERACTION AND CLINICALCHARACTERISTICS OF B7-H1 (PD-L1) EXPRESSED ON MULTIPLEMYELOMACELLS
INHIBITION OF H3K9 METHYLTRANSFERASE AS A POTENT THE-RAPEUTIC TARGET IN MULTIPLE MYELOMA
THE AP-1 TRANSCRIPTION FACTOR JUNB PROMOTES MULTIPLEMYELOMA (MM) CELL PROLIFERATION, SURVIVAL AND DRUG RE-SISTANCE IN THE BONE MARROWMICROENVIRONMENT
A NOVEL FUNCTION OF DEPTOR IN MULTIPLE MYELOMA:COMMITMENT TO PLASMACELLMATURATION
MIR-137 CONTRIBUTES TO DRUG SUSCEPTIBILITY ANDCHROMOSOMAL INSTABILITY OF MULTIPLE MYELOMA THROUGHTARGETINGAURKA
SURGICAL CONTROL/CURE OF 5TGM1 MURINE MULTIPLEMYELOMAMODEL BY THYROPARATHYROIDECTOMY
MMSET I ACTS AS AN ONCOGENE IN T(4;14) MULTIPLE MYELOMACELLS
EFFECTIVE IMPAIRMENT OF MYELOMA PROGENITORS BY HY-PERTHERMIA: AUGMENTATION WITH BORTEZOMIB AND PIM IN-HIBITION IN COMBINATION
PRECLINICALANTIMYELOMAACTIVITY OF EDO-S101
BONE MARROW ANGIOGENIC POTENTIAL AND MOLECULAR EX-PRESSION OF CELL-CELL ADHESION MOLECULES AND MATRIX-METALLO PROTEINASES IN MULTIPLE MYELOMA
CANCER-TESTIS ANTIGEN SLLP1 REPRESENTS A PROMISINGTARGET FOR THE IMMUNOTHERAPY OF MULTIPLE MYELOMA
PRL-3 INCREASES SURVIVAL OF MULTIPLE MYELOMA CELLSTHROUGH SRCACTIVATION
A NOVEL HUMAN FC-OPTIMIZED ICAM-1/CD54 ANTIBODY (MSH-TP15E) WITH POTENT ANTI-MYELOMA ACTIVITY IN VITRO AND INVIVO
V.C. Ramani
C. Pawlyn
S. Hernández-García
M. Ishibashi
J. Devin
F. Fan
D. Quwaider
Y. Qin
M. Zangari
Z. Xie
H. Miki
A.A. López-IglesiasM.C. Rapanotti
S. Yousef
P. Abdollahi
K. Klausz
PO-227
PO-228
PO-229
PO-230
PO-231
PO-232
PO-233
PO-234
PO-235
PO-236
PO-237
PO-238
PO-239
PO-240
PO-241
PO-242
FUNCTIONAL MAPPING OF MULTIPLE MYELOMA KINOME WITHLIBRARY OF SMALLMOLECULE INHIBITORS
IDENTIFICATION OF FAM46C AS A TUMOR SUPPRESSOR INMULTIPLE MYELOMA
TARGETING MYC VIAARK5 IN MULTIPLE MYELOMA
ADOPTIVE B-CELL TRANSFER MOUSE MODEL OF HUMANMYELOMA
CYTOTOXIC CD8+ T CELLS IN MYELOMA ARE IN A STATE OFTELOMERE-INDEPENDENT SENESCENCE RATHER THAN ANEXHAUSTED OR ANERGIC STATE: IMPLICATION FOR IMMUNECHECKPOINT BLOCKADE
ANTI-MYELOMA ACTIVITY OF CS-1-SPECIFIC CHIMERIC ANTIGENRECEPTOR (CAR) EXPRESSING T CELLS IN VITRO AND IN PRE-CLINICAL IN VIVO MODELS
ROLE OF RECQ1 HELICASE IN MULTIPLE MYELOMA DRUG RE-SISTANCE
A PLASTIC SQSTM1/P62-DEPENDENT AUTOPHAGIC RESERVEMAINTAINS PROTEIN HOMEOSTASIS AND DETERMINESPROTEASOME INHIBITOR SUSCEPTIBILITY IN MULTIPLE MYELOMACELLS
TOP2A KNOCKDOWN RESENSITIZES CARFILZOMIB-RESISTANTHMCLS TO CARFILZOMIB
IMIDS INDUCED IKAROS-DEPENDENT DOWNREGULATION OF MYCIN MYELOMA IS MEDIATED THROUGH THE REPRESSION OF THE 3’IGH ENHANCER ACTIVITY AND THE NURD COMPLEX REPO-SITIONING
GRANULOCYTE-LIKE MYELOID DERIVED SUPPRESSOR CELLS (G-MDSCS) ARE INCREASED IN MULTIPLE MYELOMA DUE TO IMMU-NOLOGICAL DYSREGULATION OF MESENCHYMAL STEM CELLS(MSCS)
TARGETING THE WNT CANONICAL PATHWAY IN MULTIPLEMYELOMA (MM) WITH BC2059, A NEW ORALLY BIOAVAILABLE Β-CATENIN INHIBITOR
TRAMETINIB COMBINED WITH DEXAMETHASONE INDUCES BIM-DEPENDENT SYNERGISTIC KILLING OF PREVIOUSLY DEXA-METHASONE-REFRACTORY MYELOMA
E. Dhimolea
Y.X. Zhu
S. Parekh
S. Janz
H. Suen
T. Gogishvili
E. Viziteu
T. Perini
A. Reale
P. Neri
C. Giallongo
I. Savvidou
T. Khong
BP-031
BP-032
BP-033
BP-034
BP-035
BP-036
BP-037
BP-038
BP-039
BP-040
PO-224
PO-225
PO-226
4. Multiple Myeloma Biology, Pathophysiology, Preclinical Studies, Bone Disease
POSTER DISCUSSION SESSIONChairman: Noopur Raye
POSTER SESSION
6160
15TH INTERNATIONALMYELOMAWORKSHOP Auditorium Parco della Musica
SEPTEMBER 23-26, 2015
TARGETING OF BMI-1 BY THE SMALL MOLECULE INHIBITOR PTC-209 DEMONSTRATES POTENTANTI-MYELOMAACTIVITY IN VITRO
GDF15 PROMOTES OSTEOCLAST DIFFERENTIATION AND HIGHSERUM GDF15 LEVELS ARE ASSOCIATED WITH MULTIPLEMYELOMABONE DISEASE
TARGETING METABOLISM IN MULTIPLE MYELOMA ENHANCES BIMBINDING TO BCL-2 ELICITING SYNTHETIC LETHALITY TOABT-199
GRP78 (78-KDAGLUCOSE-REGULATEDPROTEIN) ISAPOTENTIALLYUSEFUL BIOMARKER FOR PREDICTING RESPONSEAND SURVIVALOUTCOME IN PATIENTS WITH MULTIPLE MYELOMA, AND IS A PO-TENTIALLY USEFUL TARGET IN THE TREATMENT OF MULTIPLEMYELOMA
BORTEZOMIB-ANDCARFILZOMIB-RESISTANTMULTIPLEMYELOMACELLSGENERATED IN VITROMATCHTHEMOLECULARHALLMARKSOF BORTEZOMIB-RESISTANT PRIMARY MYELOMA CELLS, BUTDIFFER INTHEIR SENSITIVITYTO BORTEZOMIB, CARFILZOMIBANDNOVEL PROTEASOME INHIBITING DRUGS
L-PLASTIN FUNCTION IN DRUGRESISTANCEAND IMMUNESYSTEMRESISTANCE
NOTCH SIGNALING DYSREGULATION PROMOTES MULTIPLEMYELOMA-ASSOCIATED BONE DISEASE
NOTCH PATHWAY AND INTELEUKIN-6 COOPERATE TO SUPPORTMULTIPLE MYELOMACELL PROLIFERATION
FOXM1 IS A THERAPEUTIC TARGET IN HIGH-RISK MULTIPLEMYELOMA
STK405759 ASANOVELDRUG FORMULTIPLE MYELOMATHERAPY
FREQUENCY OF PROTEASE ACTIVATED RECEPTOR1 (PAR1) EX-PRESSION AND THE IN VITRO EFFECTS OF XT5 AND XT2B, TWONOVELPAR1BINDINGMOLECULES, ONPRIMARYANDBORTEZOMIBREFRACTORYMYELOMACELL LINES
CO-INHIBITORY MOLECULE VSIG4 NEGATIVELY REGULATESHELPER T CELL-DEPENDENT ISOTYPE SWITCHINGANDANTIBODYRESPONSE
BORTEZOMIB INHIBITS OSTEOCLASTOGENESIS AND BONE RE-SORPTION THROUGH MODULATION OF CHIT1 AND YKL40 EX-PRESSION
SURVIVIN SUPPRESSANT YM155 INDUCES CELL DEATH VIA PRO-TEASOMAL DEGRADATION OF C-MYC IN MULTIPLE MYELOMACELLS
CD229 IS EXPRESSED ON THE SURFACE OF PLASMA CELLSCARRYING AN ABERRANT PHENOTYPE AND CHEMOTHERAPY-RESISTANT PRECURSOR CELLS IN MULTIPLE MYELOMA
A. Bolomsky
M. Westrin
R. Bajpai
H. Quach
L. Besse
N. Aouali
S. Garavelli
S. Galletti
C. Gu
G. Rozic
M. Beksac
K. Jung
D. Tibullo
M. Asahi
S. Yousef
PO-259
PO-260
PO-261
PO-262
PO-263
PO-264
PO-265
PO-266
PO-267
PO-268
PO-269
PO-270
PO-271
PO-272
PO-273
IDENTIFICATION OF FAM46CASATUMOR SUPPRESSOR INMULTIPLE MYELOMA
THENOVELPAN-PIM KINASE INHIBITOR, LGH447, SHOWSDUALAN-TITUMORAL AND BONE ANTIRESORPTIVE EFFECT IN MULTIPLEMYELOMA AND SYNERGIZES WITH STANDARD-OF-CARETREATMENTS
HISTONE DEACETYLASE 11 (HDAC11) IS CRITICAL FOR PLASMACELL DEVELOPMENTAND MULTIPLE MYELOMASURVIVAL
MULTIPLE MYELOMA (MM) PATIENTS IN LONG TERM COMPLETEREMISSION (LTCR) AFTER AUTOLOGUS TRANSPLANTATIONEXPRESSADISTINCTIVE INMUNE “FOOTPRINT”. ASINGLE CENTREEXPERIENCE
HIGH LEVELS OF PERIOSTIN IN PATIENTS WITH MULTIPLEMYELOMACORRELATEWITH LOW BONE FORMATION, INCREASEDFRACTURE RATEAND DIFFUSE MRI PATTERN
A NOVEL 3D HIGH-THROUGHPUT COCULTURE PLATFORM FORMULTIPLE MYELOMA EX-VIVO SENSITIVITY TESTING AND DRUGSCREENING
MULTIPLEMYELOMADRUGRESISTANCE:ALLROADS LEADTOKLF9
OSTEOPROTEGERIN ISASIGNIFICANT PROGNOSTIC FACTOR FOROVERALL SURVIVAL IN PATIENTS WITH PRIMARY SYSTEMIC AMY-LOIDOSIS INDEPENDENT OF THE MAYO STAGING
THE KCA2.3 POTASSIUM CHANNEL AT 1Q21 IS ASSOCIATED WITHDISEASE PROGRESSION AND REDUCED SURVIVAL DURINGRELAPSE IN MULTIPLE MYELOMA
IN VIVO FLUORESCENT IMAGINGOFMULTIPLEMYELOMA IN TRAN-SPARENTIZING XENOGRAFT MODEL
CHARACTERIZATION OF TCR REPERTOIRE OF CD4+ AND CD8+ TCELLS FROM PATIENTS WITH MULTIPLE MYELOMA IN SUSTAINEDCOMPLETE REMISSION
RASSF4 FUNCTIONS AS A TUMOR SUPPRESSOR IN MULTIPLEMYELOMA
NOTCH SIGNALING DRIVES MYELOMA CELLS HOMING TO THEBONE MARROW BY REGULATING THE CXCR4/CXCL12 AXIS
IDENTIFYINGDISEASEPROGRESSIONEVENTS INMULTIPLEMYELOMA
SCLEROSTIN REMAINS ELEVATED EVEN IN THE PLATEAU PHASEOF MYELOMA PATIENTS: IMPLICATIONS INTO THE PATHOGENESISOF OSTEOBLAST DYSFUNCTION OF MULTIPLE MYELOMA
BETBROMODOMAIN BLOCKADEENHANCES IKAROS INHIBITIONBYLENALIDOMIDE THERAPY PROVIDING ADDITIONAL ACTIVITY IN INVITROAND IN VIVO MODELS OF MULTIPLE MYELOMA
Y.X. Zhu
T. Paíno
J. Brayer
A. Arteche
E. Terpos
J.M. Wal-dschmidt
M. Nikiforov
E. Kastritis
H.M. Nurul
Y. Mishima
E. Lozano
E. De Smedt
M. Colombo
A. Brown
E. Terpos
T. Diaz
PO-243
PO-244
PO-245
PO-246
PO-247
PO-248
PO-249
PO-250
PO-251
PO-252
PO-253
PO-254
PO-255
PO-256
PO-257
PO-258
6362
15TH INTERNATIONALMYELOMAWORKSHOP Auditorium Parco della Musica
SEPTEMBER 23-26, 2015
CHARACTERIZATION OF HEAT SHOCK FACTOR 1 IN RESPONSE TOPROTEASOME INHIBITION UNVEILS A NOVEL THERAPEUTICSTRATEGY FOR MULTIPLE MYELOMATREATMENT
BUFALIN INDUCESAPOPTOSIS INMYELOMACELLS THROUGHDNADAMAGEAT HYPOXIC CONDITIONS
AUTOLOGOUSACTIVATEDANDEXPANDEDNATURALKILLERCELLSDESTROY MULTIPLE MYELOMA CLONOGENIC TUMOR CELLSTHROUGH NKG2DAND ITS LIGANDS
CLINICOPATHOLOGICAL ANALYSIS OF MULTIPLE MYELOMA WITHCENTRAL NERVOUS SYSTEM INVOLVEMENT
LENALIDOMIDE INCREASESHUMANDENDRITIC CELLMATURATIONMODULATING BOTH MONOCYTE DIFFERENTIATION AND ME-SENCHYMAL STROMALCELL INHIBITORY PROPERTIES BY IKAROSDEPENDENTAND INDEPENDENT MECHANISMS
COMPARISON OF POLYCLONAL AND MONOCLONAL ANTIBODYBASED FREE LIGHT CHAIN ASSAYS TAKING ACCOUNT OF RENALFUNCTION
STRUCTURAL CHARACTERISATION OF IMMUNOGLOBULIN G GLY-COSYLATION IN MULTIPLE MYELOMA
C-METASSOCIATEDWITH OSTEOGENESIS IN MULTIPLE MYELOMAPATIENTS BY INDUCTIONOFMMP9 EXPRESSIONBYHGF IN BMSCS
EXPRESSION OF CANCER TESTIS ANTIGENS (CTAS) IN PLA-SMACYTOMAWITHANDWITHOUT BONE MARROW INVOLVEMENT
INCREASED DNP73 PROMOTES MYELOMA CELL GROWTH ANDREPRESSES DNADAMAGE-INDUCEDAPOPTOSIS
CLONAL EVOLUTIONAL PATHS IN MULTIPLE MYELOMA REVEALEDIN SINGLE CELL OF SEQUENTIAL ANALYSIS AND ITS CLINICAL SI-GNIFICANCE
IMPACTOF LENALIDOMIDEANDDEXAMETHASONETREATMENTONIMMUNE CELL POPULATIONS OF THE PATIENTS WITH RE-FRACTORY/RELAPSED MULTIPLE MYELOMA
TARGETAND RESISTANCE RELATED PROTEINS OF RECOMBINATEMUTANTHUMANTUMORNECROSIS FACTOR-RELATEDAPOPTOSIS-INDUCING LIGAND (RMHTRAIL) ON MYELOMACELL LINES
AMILORIDE INDUCESPOTENTANTITUMORALACTIVITY INMULTIPLEMYELOMATHROUGH THE REACTIVATION OF MUTANT P53
CDC37 SUPPRESSING IN MULTIPLE MYELOMA BLOCKS PROLI-FERATION BUT INDUCES BORTEZOMIB RESISTANCE
SERUMCYTOKINE LEVELS IN PATIENTSOFMULTIPLEMYELOMAATDIAGNOSIS ANDAT RELAPSE
S. Shah
E. Fujii
A. Leivas
S. Morita
F. Costa
O. Decaux
G.N. Le
H. Park
A. Jungbluth
M. Hao
X. Qin
C.K. Min
Y. Jian
E. Rojas
M. Zang
S. Jasrotia
PO-289
PO-290
PO-291
PO-292
PO-293
PO-294
PO-295
PO-296
PO-297
PO-298
PO-299
PO-300
PO-301
PO-302
PO-303
PO-304
THECHEMOKINECXCL9 (MIG) ISAN INDEPENDENTPREDICTOROFOVERALL SURVIVAL IN NEWLY DIAGNOSED MULTIPLE MYELOMA
N-CADHERIN IS A THERAPEUTIC TARGET IN T(4;14)-POSITIVEMULTIPLE MYELOMA
MYELOMA-DERIVED CCL27 INDUCES STROMA-DEPENDENT RE-SISTANCEAGAINST BORTEZOMIB VIAUPREGULATION OF IL-10
POTENTIAL ROLE OF EXOSOME-ASSOCIATED MICRORNA PANELSAND IN VIVO ENVIRONMENT TO PREDICT DRUG RESISTANCE FORPATIENTS WITH MULTIPLE MYELOMA IN THE ERA OF NOVELAGENTS: A RETROSPECTIVE ANALYSIS OF REAL-WORLD DATAFROMACHINESE CENTER OF HEMATOLOGICAL DISEASE
INVOLVEMENT OF NOTCH SIGNALING IN MULTIPLE MYELOMAAN-GIOGENESIS AND PROGRESSION
INHIBITIONOFMTORASANTIANGIOGENIC STRATEGY INMULTIPLEMYELOMA
CORRELATIONOFTHEPARAMETERSOFMYELOMABONEDISEASESIGNALLINGTOTHEACTIVITYOFMULTIPLEMYELOMAANDTOTHERISK OF TRANSFORMATION IN MONOCLONAL GAMMOPATHY OFUNDETERMINED SIGNIFICANCE
ROLE OF NUCLEAR HEME OXYGENASE 1 (HO-1) IN BORTEZOMIBINDUCED CELL DEATH AND GENOMIC INSTABILITY OF MULTIPLEMYELOMA (MM) CELLS
HUWE1 IS A POTENTIAL THERAPEUTIC TARGET IN MULTIPLEMYELOMA
EXPRESSIONAND FUNCTIONOFSLAMFAMILYMOLECULE SLAMF3(CD229) IN MYELOMA
DEFICIENCY IN DNA REPAIR PATHWAYS OF PERIPHERAL BLOODMONONUCLEAR CELLS CORRELATES WITH BETTER CLINICALOUTCOME OF MYELOMAPATIENTS
ALTERATION OF PIM-2 EXPRESSION BY CLINICALLY AVAILABLEANTI-MYELOMAAGENTS: COMBINATORYANTI-MYELOMAEFFECTSWITH PIM INHIBITION
RELATION BETWEEN LYMPHOCYTES AND DENDRITIC CELLS - IM-PLICATIONS FORTHE EFFECTIVENESSOFAN IMMUNE RESPONSETO NEOPLASTIC ANTIGENS IN PATIENTS SUFFERING FROMMULTIPLE MYELOMA
THE MECHANISMS AND EFFECTS OF LONG NONCODING RNAMA-TERNALLY EXPRESSED 3 IN MULTIPLE MYELOMA
THE CURRENT UNMET MEDICAL NEEDS IN THE TREATMENT ANDMANAGEMENT OF MULTIPLE MYELOMA (MM)
A. Bolomsky
K.M. Mrozik
S. Thangavadivel
L. Zhang
I. Saltarella
A. Lamanuzzi
J. Minarik
D. Tibullo
L.J. Crawford
A. Yamada
M. Gkotzamanidou
N. Shingen
E. Grywalska
X. Qu
P.G. Richardson
PO-274
PO-275
PO-276
PO-277
PO-278
PO-279
PO-280
PO-281
PO-282
PO-283
PO-284
PO-285
PO-286
PO-287
PO-288
6564
15TH INTERNATIONALMYELOMAWORKSHOP Auditorium Parco della Musica
SEPTEMBER 23-26, 2015
LENALIDOMIDE-DEXAMETHASONE OR MELPHALAN-LENALIDO-MIDE-PREDNISONE (MPR)ORCYCLOPHOSPHAMIDE-PREDNISONE-LENALIDOMIDE (CPR) FOR INITIAL TREATMENT OF REAL LIFEELDERLYPATIENTSWITHNEWLYDIAGNOSEDMULTIPLEMYELOMA
AGE VERSUS FRAILTY. WHAT SHOULD DETERMINE TREATMENTCHOICE IN THE ELDERLY MYELOMAPATIENTS THESE DAYS?
WEEKLY CARFILZOMIB IN COMBINATION WITH CYCLOPHOSPHA-MIDE AND DEXAMETHASONE (WCCYD) IN PATIENTS (PTS) WITHNEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): A PHASE 1/2STUDYOF THE EUROPEANMYELOMANETWORK TRIALIST GROUP
BENDAMUSTINE, BORTEZOMIB AND DEXAMETHASONE (BBD) ASFIRST-LINE TREATMENT OF PATIENTS (PTS) WITH MULTIPLE MYE-LOMA (MM) WHO ARE NOT CANDIDATES FOR HIGH DOSE CHEMO-THERAPY
9-YEAR FOLLOW-UP BORTEZOMIB, THALIDOMIDE, DEXAMETHA-SONE INDUCTION THERAPY FOLLOWED BY MELPHALAN, PREDNI-SOLONE, THALIDOMIDECONSOLIDATIONTHERAPYASAFIRSTLINEOF TREATMENT FOR PATIENTS WITH MULTIPLE MYELOMA WHOARE NON-TRANSPLANT CANDIDATES: RESULTS OF THE KOREANMULTIPLE MYELOMAWORKING PARTY (KMMWP)
RANDOMIZEDPHASE II TRIALOFCOMBINATION IDIOTYPEVACCINEAND ANTI-CD3/ANTI-CD28 COSTIMULATED AUTOLOGOUS T CELLSIN PATIENTS WITH MULTIPLE MYELOMA POST-AUTOTRANSPLAN-TATION
ARANDOMIZED PHASE III TRIAL OF BUSULFAN + MELPHALAN (BU-MEL) VS MELPHALAN ALONE FOR MULTIPLE MYELOMA: LONGERPFS IN THE BU-MELARM
MATCHED-PAIRS ANALYSIS OF OUTCOMES WITH BORTEZOMIB,MELPHALAN,AND PREDNISONE (VMP) TREATMENT FOR PREVIOU-SLY UNTREATED MULTIPLE MYELOMA (MM) USING LONG-TERMFOLLOW-UPDATAFROMTHEPHASE 3 VISTAANDPETHEMA/GEM05TRIALS
CLINICAL IMPACT OF DEPTH OF RESPONSE ON 3 MONTHS AFTERSTARTING CHEMOTHERAPY AND CUMULATIVE DOSE OF BORTE-ZOMIB ON SURVIVAL IN ELDERLY PATIENTS WITH MULTIPLE MYE-LOMA WHO TREATED WITH BORTEZOMIB COMBINED MELPHALANPLUS PREDNISOLONE ; HOW TO IMPROVE SURVIVAL RATES BYLONGER DURATION OF TREATMENT AND EARLY DEEPER RE-SPONSE
HIGH VERSUS ATTENUATED DOSE DEXAMETHASONE HAS LITTLEEFFECT ON THE SPEED OR DEPTH OF RESPONSE TO INDUCTIONTHERAPY FOR MYELOMA
V. Magarotto
S.G.R. Verelst
S. Bringhen
J.G. Berdeja
E. Lee
M.H. Qazilbash
M.H. Qazilbash
M.V. Mateos
H.S. Lee
H. Giles
BP-041
BP-042
BP-043
BP-044
BP-045
BP-046
BP-047
BP-048
BP-049
BP-050
A NOVEL SMALL MOLECULE COMPOUND DISPLAYS PRECLINICALACTIVITYAGAINSTMULTIPLEMYELOMABYDISRUPTINGTHEMTORSIGNALING PATHWAY
THE RELATIONSHIP OF MYELOMA BONE DISEASE SIGNALLING TOTHE PARAMETERS OF BONE METABOLISM IN MONOCLONAL GAM-MOPATHIES
MYELOMA IS ASSOCIATED WITH FEATURES OF METABOLICSYNDROME
NEW TARGETED DRUGS IN MULTIPLE MYELOMA THERAPY - INVITRO STUDIES
THE RELATIONSHIP OF THE PARAMETERS OF MYELOMA BONEDISEASE SIGNALLING PATHWAYS TO THE EXTENT OF BONE IN-VOLVEMENT AND EXTRAMEDULLARY DISEASE IN MONOCLONALGAMMOPATHIES
USE OF PROTEIN-TO-CREATININE RATIO IN SPOT URINE SAMPLESFOR THE EVALUATION OF PROTEINURIA IN PATIENTS WITHMULTIPLE MYELOMA
IMMUNE AND HORMONAL PECULIARITIES AND GENDER RELATEDCHANGES IN MULTIPLE MYELOMAPATIENTS
CLINICAL SIGNIFICANCE OF GRANULES IN CYTOPLASM OF NEWLYDIAGNOSED MYELOMACELLS
K. Han
J. Minarik
M.J. Streetly
C. Geraldes
J. Minarik
E. Le Mouel
H.M.M. Ali
K. Suzuki
PO-305
PO-306
PO-307
PO-308
PO-309
PO-310
PO-311
PO-312
5. Multiple MyelomaTherapy in Newly Diagnosed Patients excluding Transplantation
POSTER DISCUSSION SESSIONChairman: Heinz Ludwig
6766
15TH INTERNATIONALMYELOMAWORKSHOP Auditorium Parco della Musica
SEPTEMBER 23-26, 2015
EFFICACYANDSAFETYOFCARFILZOMIB, LENALIDOMIDE,ANDDE-XAMETHASONE (KRD) VS LENALIDOMIDE AND DEXAMETHASONE(RD) IN PATIENTS (PTS) WITH RELAPSED MULTIPLE MYELOMA(RMM) BASEDONAGE: SECONDARYANALYSIS FROMTHEPHASE 3STUDYASPIRE (NCT01080391)
SUPERIORHEALTH-RELATEDQUALITYOF LIFEWITHCARFILZOMIB,LENALIDOMIDE, AND DEXAMETHASONE VERSUS LENALIDOMIDEAND DEXAMETHASONE IN PATIENTS WITH RELAPSED MULTIPLEMYELOMA (MM): RESULTS FROM THEASPIRE TRIAL
STRATUS™ (MM-010): A SINGLE-ARM, PHASE 3B STUDY EVALUA-TING SAFETY AND EFFICACY OF POMALIDOMIDE (POM) +LOW-DOSEDEXAMETHASONE (LODEX) IN PATIENTS (PTS)WITHRE-FRACTORYORRELAPSEDANDREFRACTORYMULTIPLEMYELOMA(RRMM)
SURVIVAL OUTCOMES IN PATIENTS (PTS) WITH REFRACTORY ORRELAPSEDANDREFRACTORYMULTIPLEMYELOMA(RRMM) IN THEMM-003 TRIAL: IMPACT OF STABLE DISEASE (SD) AS A RESPONSETO POMALIDOMIDE PLUS LOW-DOSE DEXAMETHASONE (POM +LODEX)
SUBGROUP ANALYSIS BY PRIOR TREATMENT OF THE EFFICACYAND SAFETY OF PANOBINOSTAT PLUS BORTEZOMIB AND DEXA-METHASONE IN PATIENTSWITHRELAPSEDORRELAPSEDANDRE-FRACTORY MULTIPLE MYELOMA IN THE PANORAMA1 STUDY
SAFETY PROFILE OF ORAL IXAZOMIB: EXPERIENCE FROM 761 PA-TIENTS (PTS) ACROSS 14 PHASE 1 OR PHASE 1/2 CLINICAL STU-DIES
EXPOSURE-RESPONSE RELATIONSHIP OF DARATUMUMAB EFFI-CACYANDSAFETY IN PATIENTSWITHRELAPSEDORREFRACTORYMULTIPLEMYELOMA(MM)AFTERPRIORPROTEASOME INHIBITORS(PIS) AND IMMUNOMODULATORY DRUGS (IMIDS)
A PHASE I/IIA STUDY OF THE HUMAN CD38 ANTIBODY MOR202(MOR03087) IN RELAPSED OR REFRACTORYMULTIPLE MYELOMA
IBRUTINIB IN COMBINATIONWITH LOW-DOSEDEXAMETHASONE INPATIENTSWITHRELAPSEDORRELAPSEDANDREFRACTORYMUL-TIPLE MYELOMA: RESULTS FROMAMULTICENTER PHASE 2 TRIAL
PHASE I INTERIM SAFETY AND EFFICACY OF VENETOCLAX (ABT-199/GDC-0199) MONOTHERAPYFORRELAPSED/REFRACTORY (R/R)MULTIPLE MYELOMA (MM)
A. Palumbo
A.K. Stewart
M.A. Dimopoulos
P. Moreau
P.G. Richardson
S. Lonial
X.S. Xu
M.S. Raab
P.G. Richardson
S. Kumar
BP-051
BP-052
BP-053
BP-054
BP-055
BP-056
BP-057
BP-058
BP-059
BP-060
TREATMENT OF RENAL FAILURE IN PATIENTS WITH NEWLY DIA-GNOSED MULTIPLE MIELOMA WITH BORTEZOMIB AND DEXAME-THASONE: RESULTS OF A PHASE II TRIAL FROM PETHEMA/GEMGROUP (RENVEL)
RAPID REDUCTION IN IFLC PREDICTS ACHIEVEMENT OF VGPRAFTER 4 CYCLES OF VCD TREATMENT: SHIMOUSA MM-01 VCDSTUDY
LENALIDOMIDE DOSE MODIFICATIONS AND ASSOCIATED PATIENTOUTCOMES IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM)
INTENTION TO TREAT VS AGE OF DIAGNOSIS. ANALYSIS OF BENE-FITIAL EFFECTOFNEWAGENTS INTHETREATMENTOFNEWLYDIA-GNOSED MULTIPLE MYELOMA (NDMM)
PATTERNS OF GROWTH FACTOR COSTS IN MULTIPLE MYELOMAPATIENTS TREATEDWITH LENALIDOMIDE OR BORTEZOMIB
CYCLOPHOSPHAMIDE, BORTEZOMIB AND DEXAMETHASONE (CY-BORD) FOR THE UPFRONT THERAPY OF TRANSPLANT INELIGIBLEPATIENTS WITH MULTIPLE MYELOMA
SURVIVAL OF PATIENTS WITH MULTIPLE MYELOMA IN FIRST-LINETREATMENT: THALIDOMIDE, DEXAMETHASONE AND ZOLEDRONICACID. REPORT OF THE NATIONAL CANCER INSTITUTE OF MÉXICO(INCAN)
INCIDENCE AND CHARACTERISTICS OF BACTERIAL INFECTIONSDURING INDUCTION THERAPY IN PATIENTS WITH MULTIPLE MYE-LOMATREATEDWITHNEWDRUGS.ASTUDYOF 67 PATIENTS FROMASINGLE INSTITUTION
CYBORD DEMONSTRATED ITS SUPERIORITY TO BORTEZOMIBPLUSDEXAMETHASONE INTRANSPLANT-ELIGIBLE PATIENTSWITHNEWLY DIAGNOSED MULTIPLE MYELOMA
OUTCOMES BETWEEN FRONTLINE AND SALVAGE BORTEZOMIB-BASED REGIMENS IN ELDERLY PATIENTS WITH MULTIPLE MYE-LOMA
RESULTS OF THE PROTOCOL VCD FOR MULTIPLE MYELOMA IN ASINGLE CENTER INALGERIA
IMPROVED OUTCOME BY EARLY DOSE REDUCTION AND SCHE-DULEADJUSTMENTWITH SUBCUTANEOUS INJECTION OF BORTE-ZOMIB IN ELDERLY MYELOMA PATIENTS RECEIVINGBORTEZOMIB-MELPHALAN-PREDNISONE REGIMEN
L. Rosiñol
M. Takeuchi
S. Usmani
V. MartínezRobles
S.R. Arikian
C.P. Venner
J.R. EspinozaZamora
M.F. MartínezGarcia
Y. Kusano
S.K. Sohn
M.T. Abad
H.J. Shin
PO-313
PO-314
PO-315
PO-316
PO-317
PO-318
PO-319
PO-320
PO-321
PO-322
PO-323
PO-324
6. Multiple Myeloma Therapy Relapsed/Refractory Patients
POSTER DISCUSSION SESSIONChairman: Torben Plesner
POSTER SESSION
6968
15TH INTERNATIONALMYELOMAWORKSHOP Auditorium Parco della Musica
SEPTEMBER 23-26, 2015
0052) PLUS LOWDOSEDEXAMETHASONE (DEX) IN PATIENTSWITHRELAPSED AND REFRACTORY MULTIPLE MYELOMA; STUDY NPI-0052-101 (NCT00461045)
PHASE 1B INTERIM RESULTS: VENETOCLAX (ABT-199/GDC-0199) INCOMBINATION WITH BORTEZOMIB (BTZ) AND DEXAMETHASONE(DEX) IN RELAPSED/REFRACTORY (R/R) MULTIPLE MYELOMA (MM)
OPROZOMIB (OPZ)ANDDEXAMETHASONE (DEX) IN PATIENTS (PTS)WITH RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA(RRMM): UPDATED RESULTS FROM A PHASE 1B/2, MULTICENTER,OPEN-LABEL STUDY
OUTCOME OF FIRST SALVAGE THERAPY FORMULTIPLE MYELOMA(MM) IN REAL-WORLD CLINICAL PRACTICE: RESULTS FROM THETHIRD INTERIM ANALYSIS OF THE MULTINATIONAL, OBSERVATIO-NAL, NON-INTERVENTIONAL EMMOS STUDY
THE BRUTON’S TYROSINE KINASE INHIBITOR IBRUTINIB IN COMBI-NATION WITH CARFILZOMIB IN PATIENTS WITH RELAPSED OR RE-LAPSEDANDREFRACTORYMULTIPLEMYELOMA: INITIALRESULTSFROMAMULTICENTER PHASE 1/2B STUDY
VORINOSTAT (V), BORTEZOMIB (B), DOXORUBICIN (DOX) AND DE-XAMETHASONE (DEX, VBDD) IN RELAPSEDORREFRACTORYMUL-TIPLE MYELOMA PATIENTS (PTS): RESULTS OF AN OPEN,NON-COMPARATIVE, PHASE I/II INVESTIGATOR INITIATEDTRIAL (IIT)
OUTCOMEOFTREATMENTFOR FIRSTVERSUS LATERRELAPSE INMULTIPLE MYELOMA (MM) IN REAL-WORLD CLINICAL PRACTICE:RESULTS FROM THE THIRD INTERIM ANALYSIS OF THE MULTINA-TIONAL, NON-INTERVENTIONAL, OBSERVATIONAL EMMOS STUDY
OPTIMALSEQUENTIALTHERAPY IN FIRSTLINEANDFIRSTRELAPSEOF MM: APOST-HOCANALYSIS
PATTERNS OF RELAPSE AND OUTCOME OF ELDERLY MULTIPLEMYELOMA PATIENTS TREATED WITH VMP OR VTP AS INDUCTIONFOLLOWED BY MAINTENANCE WITH VT OR VP IN THE SPANISHGEM2005MAS65 TRIAL
CD34-SELECTEDALLOGENEIC HEMATOPOIETIC STEM CELLTRAN-SPLANTATION FOR PATIENTS WITH RELAPSED, HIGH-RISK MULTI-PLE MYELOMA
A PHASE 1, OPEN-LABEL, DOSE ESCALATION, SAFETY, PHARMA-COKINETICAND PHARMACODYNAMIC STUDYOFAFIRST IN CLASSPOL1 INHIBITOR (CX-5461) IN PATIENTS WITH ADVANCED HAEMA-TOLOGIC MALIGNANCIES (HM)
HIGHLY PROLONGED OVERALL SURVIVAL FOLLOWING REDUCEDINTENSITYALLOGENEIC STEMCELLTRANSPLANTATION FORMUL-TIPLE MYELOMA IN THE NEW DRUGS ERA
P. Richardson
C. Touzeau
C. Paba Prada
M. Mohty
A. Chari
A. Keller
M. Mohty
M. Offidani
A. López
G. Koehne
A. Khot
F. Rezzonico
PO-336
PO-337
PO-338
PO-339
PO-340
PO-341
PO-342
PO-343
PO-344
PO-346
PO-347
PO-348
ADVERSE EVENT (AE) MANAGEMENTWITH POMALIDOMIDE (POM)+ LOW-DOSEDEXAMETHASONE (LODEX) IN THESTRATUS™TRIAL:A PHASE 3B STUDY EVALUATING SAFETY AND EFFICACY IN PA-TIENTS (PTS) WITH REFRACTORY OR RELAPSED AND REFRAC-TORY MULTIPLE MYELOMA (RRMM)
TREATMENT (TX) WITH POMALIDOMIDE (POM)AND LOW-DOSE DE-XAMETHASONE (LODEX) IN PATIENTS (PTS) WITH RELAPSED ORREFRACTORY MULTIPLE MYELOMA (RRMM) AND RENAL IMPAIR-MENT (RI) INCLUDING THOSE ON DIALYSIS
A PHASE 1 STUDY OF THE PHARMACOKINETICS (PK) AND SAFETYOF POMALIDOMIDE + LOW-DOSEDEXAMETHASONE (POM+LODEX)IN PATIENTS (PTS) WITH RELAPSED OR REFRACTORY MULTIPLEMYELOMA (RRMM) AND RENAL IMPAIRMENT (RI)
OUTCOMESOFPATIENTS (PTS)WITHREFRACTORYORRELAPSEDAND REFRACTORY MULTIPLE MYELOMA (RRMM) AND RENAL IM-PAIRMENT (RI) TREATEDWITH POMALIDOMIDE (POM) + LOW-DOSEDEXAMETHASONE (LODEX) IN THE PHASE 3B STRATUS™ TRIAL(MM-010)
EFFECT OF AGE ON OUTCOMES WITH POMALIDOMIDE (POM) +LOW-DOSEDEXAMETHASONE (LODEX) IN PATIENTS (PTS)WITHRE-FRACTORYORRELAPSEDANDREFRACTORYMULTIPLEMYELOMA(RRMM) IN THESTRATUSTMTRIAL (MM-010),ASINGLE-ARM, PHASE3B STUDY
ELOTUZUMAB: SERUM PROTEIN ELECTROPHORESIS AND IMMU-NOFIXATION INTERFERENCE WITH CLINICAL ASSESSMENT OF M-PROTEIN RESPONSE IN RELAPSED/REFRACTORY MULTIPLEMYELOMA (RRMM)
LONG TERM FOLLOW-UP OF A DONOR VERSUS NO DONOR COM-PARISON IN MULTIPLE MYELOMA PATIENTS AT FIRST RELAPSEAFTER PREVIOUSAUTOTRANSPLANT
PHASE 1 CLINICAL TRIAL OF MARIZOMIB (MRZ, NPI-0052) IN PA-TIENTS WITH ADVANCED MALIGNANCIES INCLUDING MULTIPLEMYELOMA: STUDY NPI-0052-102 (NCT00629473) FINAL RESULTS
PHARMACOKINETICS OF DARATUMUMAB FOLLOWING INTRAVE-NOUS INFUSION IN RELAPSED OR REFRACTORY MULTIPLE MYE-LOMA (MM) AFTER PRIOR PROTEASOME INHIBITOR (PI) ANDIMMUNOMODULATORY DRUG (IMID) TREATMENT
BORTEZOMIB VERSUS LENALIDOMIDE IN MULTIPLE MYELOMA PA-TIENTS AT FIRST RELAPSE: FIRST INTERIM ANALYSIS OF A PHASEIII STUDY
IMPACTOFTREATMENTDURATIONANDDOSINGONEFFICACYANDSAFETY IN A PHASE 3 STUDY OF PANOBINOSTAT PLUS BORTEZO-MIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED OR RE-LAPSEDAND REFRACTORYMULTIPLE MYELOMAPHASE 1/2 DOSE-ESCALATION STUDY OF MARIZOMIB (MRZ, NPI-
M. Cavo
P. Sonneveld
J. Matous
K. Weisel
A. Palumbo
M. Dimopoulos
F. Patriarca
S.J. Harrison
P.L. Clemens
V. Montefusco
J.F. San-Miguel
PO-325
PO-326
PO-327
PO-328
PO-329
PO-330
PO-331
PO-332
PO-333
PO-334
PO-335
POSTER SESSION
7170
15TH INTERNATIONALMYELOMAWORKSHOP Auditorium Parco della Musica
SEPTEMBER 23-26, 2015
OVERCOMINGPROTEASOME INHIBITORRESISTANCE INMULTIPLEMYELOMAUSING THE XPO1: INHIBITOR SELINEXOR
POSTRANSPLANT CYCLOPHOSPHAMIDE AS GVHD PROPHYLAXISIN PATIENTSWITHMULTIPLEMYELOMA. EXPECIENCEOFASINGLECENTER
INTRAVENOUSBORTEZOMIB (IV) INFUSIONAFTERNONRESPONSETO SUBCUTANEOUS BORTEZOMIB (SQ) ADMINISTRATION CAN IN-DUCETRANSITORYRESPONSES INMULTIPLEMYELOMAPATIENTS:IS SOME PATIENT MORE SENSITIVE TO THE IV BORTEZOMIB?
APHASE I STUDYOFTHEADDITIONOFHIGH-DOSE LENALIDOMIDETO MELPHALAN CONDITIONING FOR AUTOLOGOUS STEM-CELLTRANSPLANT IN RELAPSEDORREFRACTORYMULTIPLEMYELOMA
BENDAMUSTINE-BORTEZOMIB-DESAMETASONE (BVD) IN THE MA-NAGEMENTOFRELAPSEDANDREFRACTORYMULTIPLEMYELOMA:AREGIONAL REAL-LIFE EXPERIENCE
POMALIDOMIDE-CONTAININGREGIMENS FORTHETREATMENTOFRELAPSEDAND REFRACTORYMULTIPLE MYELOMA
EFFICACYAND SAFETY OF LENALIDOMIDE (LEN) PLUS LOW-DOSEDEXAMETHASONE (DEX; RD) IN CHINESE PATIENTS (PTS)WITHRE-LAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) ACCORDINGTO DISEASE STAGE (INTERNATIONAL STAGING SYSTEM [ISS]): RE-SULTS FROM THE MM-021 TRIAL AND MM-024 EXTENDED ACCESSPROGRAM (EAP)
TWO RANDOMIZED OPEN-LABEL STUDIES OF DARATUMUMAB(DARA) PLUS STANDARD OF CARE TREATMENT VERSUS STAN-DARD OF CARE ALONE IN PATIENTS WITH PREVIOUSLY UNTREA-TED MULTIPLE MYELOMA (MM) INELIGIBLE FOR HIGH-DOSETHERAPY: 54767414MMY3007 (ALCYONE) AND 54767414MMY3008(MAIA)
MYELOABLATIVE TIMED SEQUENTIAL BUSULFAN IS SAFE IN PA-TIENTS WITH RELAPSED OR HIGH-RISK MULTIPLE MYELOMA
PEGYLATED LIPOSOMAL DOXORUBICINE, CYCLOPHOSPHAMIDEAND DEXAMETASONE (CED): A NEW OPPORTUNITY IN RELAPSEDAND REFRACTORYMULTIPLE MYELOMA
LENALIDOMIDE EXPAND CD3+CD56+ T CELL CYTOKINE INDUCEDKILLER (CIK) CELLS IN VIVO IN MULTIPLE MYELOMAPATIENTS
ORALCYCLOPHOSPHAMIDE INRELAPSED/REFRACTORYMULTIPLEMYELOMA PATIENTS WITH BIOCHEMICAL PROGRESSION DURINGLENALIDOMIDE-DEXAMETHASONETREATMENT: RESULTSOFARE-TROSPECTIVE MULTICENTERANALYSIS
MULTIPLE INFUSIONS OF AUTOLOGOUS ACTIVATED AND EXPAN-DED NATURAL KILLER CELLS: A NEW THERAPEUTIC OPTION FORMULTIPLE MYELOMA
D.M. Sullivan
L. Rosiñol
A. Gozzetti
P. Forsberg
C. Cerchione
V.H. JimenezZepeda
J. Hou
T. Facon
M.H. Qazilbash
C. Cerchione
H. Handa
L. Cesini
A. Leivas
PO-362
PO-363
PO-364
PO-365
PO-366
PO-367
PO-368
PO-369
PO-370
PO-371
PO-372
PO-373
PO-374
DURABLE REMISSION AND SURVIVAL IN RELAPSED/REFRACTORYMULTIPLE MYELOMA AFTER ALLOGENEIC HEMATOPOIETIC STEMCELL TRANSPLANTATION
AUTOPHAGY AND MTOR INHIBITION AS MECHANISMS FOR COM-BATTING CHEMORESISTANCE TO STANDARD CHEMOTHERAPY:FINAL RESULTS OF A PHASE I STUDY OF INFUSIONAL CYCLOPHO-SPHAMIDE (CY), PULSE DEXAMETHASONE (DEX), RAPAMYCIN(RAPA) AND HYDROXYCHLOROQUINE (HCQ)
WILMS’ TUMOR 1 PROTEIN IS HIGHLY EXPRESSED ON MALIGNANTPLASMA CELLS AND PROVIDES A NOVEL TARGET FOR IMMUNO-THERAPEUTICAPPROACHES
EFFICACY AND SAFETY OF PRE-APPROVAL CARFILZOMIB-BASEDTHERAPY OF MULTIPLE MYELOMA IN DAILY PRACTICE – EXPE-RIENCE FROMAGERMANACADEMIC CENTER
LOWER DOSE LENALIDOMIDE-DEXAMETHASONE IS LESS TOXICAND DOES NOT COMPROMISE EFFICACY FOR PATIENTS WITH RE-LAPSED/REFRACTORY MULTIPLE MYELOMA WHO ARE AGED ≥60YEARS AND/OR WITH RENAL IMPAIRMENT AND/OR WITH THROM-BOCYTOPENIA
SAR650984 (SAR) DIRECTLY INDUCES MULTIPLE MYELOMA (MM)CELL DEATH VIA LYSOSOMAL-ASSOCIATED AND APOPTOTIC PA-THWAYS, WHICH IS FURTHER ENHANCED BY POMALIDOMIDE
VACCINE BASED IMMUNOTHERAPY AS A STRATEGY TO BYPASSDRUG RESISTANCE IN MULTIPLE MYELOMA
IDENTIFICATION OF PRECISION TREATMENT STRATEGIES FOR HIGHRISKMULTIPLEMYELOMABYEXVIVODRUGSENSITIVITYTESTING
APHASE 1/2 TRIALOFTHE INSULINGROWTHFACTOR 1RECEPTOR(IGF-1R) INHIBITOR, LINSITINIB IN COMBINATION WITH BORTEZO-MIB (BTZ) AND DEXAMETHASONE (DEX) FOR THE TREATMENT OFRELAPSED/REFRACTORYMULTIPLE MYELOMA (MM)
THE CONTRIBUTION OF A THIRD AUTOLOGOUS STEM CELL TRAN-SPLANT IN THE ERA OF NOVEL AGENTS: FAVOURABLE OVERALLSURVIVALAND IMPROVEMENT OF EXHAUSTED BONE MARROWFUNCTION
OUTCOME OF POMALIDOMIDE THERAPY IN RELAPSED / REFRAC-TORY MYELOMA: AUK MULTI-CENTRE EXPERIENCE
RENAL RESPONSE IN PATIENTS (PTS) WITH RELAPSED REFRAC-TORY MULTIPLE MYELOMA (RRMM) AND SEVERE RENAL IMPAIR-MENT (RI): INTERIM DATA FROM A LARGE OBSERVATIONAL,PROSPECTIVE STUDY
LENALIDOMIDE LONG-TERM NEUROTOXICITY: NEUROPHYSIOLO-GICAL FOLLOW-UP STUDY IN PATIENTS WITH RELAPSED/REFRAC-TORY MYELOMA
A.M. Cornelison
E.C. Scott
G. Koehne
S. Danhof
H. Quach
H. Jiang
C. Wang
M.M. Majumder
S. Trudel
S. Strifler
N. Maciocia
A. García-Guiñon
A. Liço
PO-349
PO-350
PO-351
PO-352
PO-353
PO-354
PO-355
PO-356
PO-357
PO-358
PO-359
PO-360
PO-361
7372
15TH INTERNATIONALMYELOMAWORKSHOP Auditorium Parco della Musica
SEPTEMBER 23-26, 2015
CARFILZOMIB IN RELAPSED/REFRACTORY MULTIPLE MYELOMA,SINGLE CENTER EXPERIENCE
ECONOMIC ANALYSIS OF LENALIDOMIDE/DEXAMETHASONE(LEN/DEX) VS. BORTEZOMIB (BORT) FOR THE TREATMENT OF RE-LAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) IN CHINA
BORTEZOMIB PRETREATMENTBEFOREALLOGENIC HEMATOPOIE-TIC STEMCELLTRANSPLANTATIONFORRELAPSEDMULTIPLEMYE-LOMA
MONOCLONAL GAMMOPATHY OF RENAL SIGNIFICANCE (MGRS).RAPID HEMATOLOGICAL AND RENAL COMPLETE RESPONSE TOBORTEZOMIB
SAFETY OF LENALIDOMIDE (LEN) PLUS LOW-DOSE DEXAMETHA-SONE (DEX; RD) IN CHINESE PATIENTS (PTS) WITH RELAPSED/RE-FRACTORY MULTIPLE MYELOMA (RRMM) TREATED WITH PRIORTHALIDOMIDE (THAL) AND BORTEZOMIB (BORT): SUBANALYSIS OFTHE MM-024 EXTENDEDACCESS PROGRAM (EAP)
THE EFFICACYAND SAFETY OF LENALIDOMIDE IN MULTIPLE MYE-LOMAWITH SEVERE RENAL IMPAIRMENT
ANATIONALEXPERIENCEOFTHEEFFICACYANDSAFETYOF LONG-TERM TREATMENT WITH LENALIDOMIDE IN PATIENTS WITH RE-LAPSED MULTIPLE MYELOMA
IS URINE IMMUNOFIXATIONELECTROPHORESIS NECESSARY FORMONITORING MYELOMAPATIENTSWHO HAS UNDERGONE HEMA-TOPOIETIC STEM CELL TRANSPLANTATION
POMALIDOMIDE IN REFRACTORY MULTIPLE MYELOMA (MMRR): ASINGLE CENTER EXPERIENCE
METRONOMIC CHEMOTHERAPY OF THALIDOMIDE, CYCLOPHO-SPHAMIDE, AND DEXAMETHASONE FOR RELAPSED/REFRACTORYMULTIPLE MYELOMAPATIENTS
SYNCHRONOUS LOCALIZATIONS OF MULTIPLE MYELOMA IN 3 DIF-FERENT SITES (ETHMOIDAL SINUSES, TESTICLES AND SKIN) DU-RING THE COURSE OF MULTIPLE MYELOMA (MM) THERAPY
IGDMULTIPLEMYELOMA, DESCRIPTIVE REPORTOFEIGHTCASES,SINGLE CENTRE EXPERIENCE
CASE REPORT: POMALIDOMIDE AS CONSOLIDATION THERAPYAFTER SALVAGEAUTOLOGOUS STEM CELL TRANSPLANT
Y. Aydin
Z. Shen
S.N. Lim
A. Alegre
L. Yu
K.S. Jung
M.I. Pereira
R. Haznedar
C. MontesGaisan
H.J. Kim
G. Mele
S. Ongoren
M. Steinbach
PO-388
PO-389
PO-390
PO-391
PO-392
PO-393
PO-394
PO-395
PO-396
PO-397
PO-398
PO-399
PO-400
A SINGLE CENTRE RETROSPECTIVE ANALYSIS OF THE ADDITIONOF CLARITHROMYCIN (BIAXIN) TO LENALIDOMIDE AND DEXAME-THASONE (LEN-DEX) DURING TIME OF PROGRESSIVE DISEASE INPATIENTS WITH MULTIPLE MYELOMA (MM)
ANON-INTERVENTIONALOBSERVATIONALREGISTRYOFPATIENTS(PTS)WITHRELAPSED/REFRACTORYMULTIPLEMYELOMA(RRMM)TREATEDWITH LENALIDOMIDE (LEN)ANDDEXAMETHASONE (DEX)IN TAIWAN
A NON-INTERVENTIONAL, OBSERVATIONAL REGISTRY OF ADULTPATIENTSWITHMULTIPLEMYELOMATREATEDWITHREVLIMID (LE-NALIDOMIDE) IN CHINA: INTERIMANALYSIS
PACE AS SALVAGE THERAPY FOR RELAPSED OR REFRACTORYMULTIPLE MYELOMA
COMBINATION CARFILZOMIB AND THE VIRAL ONCOLYTIC AGENTREOLYSIN IN PATIENTS WITH RELAPSED MULTIPLE MYELOMA: APILOT STUDY INVESTIGATING VIRAL PROLIFERATION
POST-AUTHORIZATION SAFETY OF LENALIDOMIDE + DEXAMETHA-SONE IN PATIENTSWITHRELAPSED/REFRACTORYMULTIPLEMYE-LOMA IN TURKEY
EFFICACY OF POMALIDOMIDE AFTER PROGRESSION FOLLOWINGLENALIDOMIDE AND BORTEZOMIB-A MULTICENTER RETROSPEC-TIVE STUDY
LENALIDOMIDE FOR HEAVILY PRETREATED RELAPSED/REFRAC-TORYMYELOMACOHORT IN NORTHWESTUNITEDKINGDOM (UK) –EFFICACY & TOLERABILITY: HIGH RESPONSE & LOW SECOND MA-LIGNANCY RATES
EFFECTIVENESSOF LENALIDOMIDETREATMENT IN PATIENTSWITHVERYSEVERERENAL IMPAIRMENTANDRELAPSEDMULTIPLEMYE-LOMA
EFFICACYAND TOXICITYOF THE COMBINATION THERAPYOF THA-LIDOMIDE, ALKYLATING AGENT, AND CORTICOSTEROID FOR RE-LAPSED/REFRACTORYMYELOMAPATIENTS :AREPORTFROMTHEKOREAN MULTIPLE MYELOMAWORKING PARTY (KMMWP) RETRO-SPECTIVE STUDY
IMPACT OF IMMUNOGLOBULIN (IG) D SUBTYPE ON THE EFFICACYAND SAFETY OF LENALIDOMIDE PLUS LOW-DOSE DEXAMETHA-SONE (RD) IN CHINESE PATIENTS (PTS) WITH RELAPSED/REFRAC-TORY MULTIPLE MYELOMA (RRMM): MM-021 TRIAL
POMALIDOMIDE BASED THERAPY IN PATIENTS WITH SEVERERENAL IMPAIRMENT
INCIDENCE OF THROMBOSIS IN MULTIPLE MYELOMA PATIENTSTREATEDWITH LENALIDOMIDE-DEXAMETHASONE INOURCENTER.THE INFLUENCE OF RISK FACTORS
R. Kaedbey
S.Y. Huang
J. Lu
I. Isola
D.W. Sborov
A.T. FıratlıTuğlular
O. Miles
J.A. Chadwick
C. João
J. Kwon
Z. Cai
J. Richter
M. Garcia-Fortes
PO-375
PO-376
PO-377
PO-378
PO-379
PO-380
PO-381
PO-382
PO-383
PO-384
PO-385
PO-386
PO-387
7574
15TH INTERNATIONALMYELOMAWORKSHOP Auditorium Parco della Musica
SEPTEMBER 23-26, 2015
Nizar J. Bahlis Calgary, CanadaSara Bringhen Torino, ItalyRaymond L. Comenzo Boston, USAMeletios A. Dimopoulos Athens, GreeceAngela Dispenzieri Rochester, USABeth Fainan Cleveland, USAFrancesca Gay Torino, ItalyIrene M. Ghobrial Boston, USAAndrzej Jakubowiak Chicago, USATracy King Sidney, AustraliaShaji K. Kumar Rochester, USASagar Lonial Atlanta, USAValeria Magarotto Torino, ItalyMaria-Victoria Mateos Salamanca, SpainGiampalolo Merlini Pavia, ItalyFortunato Morabito Cosenza, ItalyGareth J. Morgan Little Rock, USAPellegrino Musto Rionero in Vulture (PZ), ItalyMassimo Offidani Ancona, ItalyStefania Oliva Torino, ItalyTorben Plesner Vejle, DenmarkNoopur Raje Boston, USAS. Vincent Rajkumar Rochester, USAAndrew Spencer Melbourne, AustraliaA. Keith Stewart Scottsdale, USAElena Zamagni Bologna, ItalySonja Zweegman Amsterdam, The Netherlands
7. Nurse Session
POSTER SESSION
MANAGEMENT OF TOXICITIES ASSOCIATED WITH CARFILZOMIB:AN UPDATE OF THE ITALIAN EXPERIENCE
DEVELOPING SAFE HAEMATOLOGICAL MONITORING GUIDELINESFOR PATIENTS WITH MYELOMA ON BORTEZOMIB BASEDREGIMENS
HOW A PATIENT SATISFACTION SURVEY CAN ENHANCE AMYELOMAOUT PATIENT CLINIC
ARE THE MYELOMA POPULATION COMPUTER LITERATE? –SQUASHING THE SNAIL MAIL
DEVELOPING A NURSE LED, HOLISTIC NEEDS ASSESSMENTCLINIC FOR MYELOMA PATIENTS
A. Bernardini
C. Woodrow
C. Marrin
H. King
J. Helwlett
PO-401
PO-402
PO-403
PO-404
PO-405
ABSTRACT REVIEWERS
76